

11-13-00

A

11/09/00  
JC906 U.S. PTO

Attorney Docket No. TRNSV-013BC

JC921 U.S. PTO  
09/710332  
11/09/00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
Makower, et al.	)	Art Unit: 3736
	)	
Application No.: To Be Determined	)	Examiner: Isabella, D.
	)	
Filed: Herewith	)	
	)	
For: Methods and Apparatus for	)	
Transmyocardial Direct Coronary	)	
Revascularization	)	

**Transmittal of a Continuation Utility Patent Application**

Express Mail mailing label no. EL636155782US

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Transmitted herewith for filing is the continuation utility patent application for "Methods and Apparatus for Transmyocardial Direct Coronary Revascularization."

- ☒ The applicant(s) hereby request(s) the filing of the continuation patent application under 37 CFR §1.53(b) corresponding to application Serial No. 09/059,531 which was a continuation-in-part of application Serial No. 08/730,327, filed October 11, 1996, 08/730,496, filed October 11, 1996 and 08/837,295, filed April 11, 1997. No amendments referred to in the oath or declaration filed to complete the prior application introduced new matter therein.
- ☒ In accordance with Rule 136, the Commissioner is hereby petitioned for a **3** month extension of time, extending to **November 9, 2000** the period for response to the Office action dated **May 9, 2000**. Check No. 2032 for \$ 445.00 is enclosed.
- ☒ A true copy of the following are enclosed:
  - ☒ the prior application as filed, including all 76 pages of specifications (including 57 pages of written description; 17 pages of claims (Claims 1-83) and all 15 sheets of informal drawings; and

- ☒ the declaration of inventorship showing the signatures or an indication it was signed.
- ☐ Please delete the names of the following persons who are not inventors of the invention being claimed in this divisional application:
- ☒ Please amend the specification after the granting of a filing date herein by deleting the paragraph after the heading "Related Applications" and inserting the sentence: --This is a continuation of application Serial No. 09/059,531 which was a continuation-in-part of application Serial No. 08/730,327, filed October 11, 1996, 08/730,496, filed October 11, 1996 and 08/837,295, filed April 11, 1997.--.
- ☒ Kindly enter in this continuation application the following preliminary amendment, prior to calculation of the required filing fee:

**IN THE CLAIMS:**

**Please cancel claims 29-83, without prejudice.**

- ☒ Check No. 2033 covering the filing fee in the amount of \$472.00 accompanies this application, calculated as follows:


For	(Col. 1) No. Filed	(Col. 2) No. extra	Small entity Rate	Fee	Or	Other than a Small entity Rate	Fee
Basic fee				\$ 355	Or		\$ 710
Total claims	28	- 20 =	8	x 9	\$ 72	Or	x 18 \$
Indep claims	1	- 3 =	0	x 40	\$	Or	x 80 \$
_ Multiple dependent claims presented			+ 135	\$	Or	+ 270	\$
			Total	\$ 472	Or	Total	\$

- ☐ An Assignment of the invention to [Assignee], including a cover sheet and Check No. [Assignment Check No.] for \$40 are enclosed.
- ☐ A Statement of Ownership and Power of Attorney.
- ☒ The Commissioner is hereby authorized to charge any underpayment and credit any overpayment of the filing fees required under 37 CFR § 1.16 and any patent application processing fees required under 37 § CFR 1.17 to Deposit Account No. 50-0878.
- ☐ Formal drawings are enclosed.

- ☒ The undersigned is the Applicant's attorney of record in the prior application, and all future communications should be addressed to the undersigned at the new address shown herebelow.
- ☒ The statement(s) of Small Entity Status filed in the prior application is no longer proper and is hereby withdrawn.
- ☒ An information disclosure statement is enclosed and PTO form 1449.

STOUT, UXA, BUYAN & MULLINS, LLP

Date: November 9, 2000

  
Robert D. Buyan, Reg. No. 32,460

4 Venture, Suite #300  
Irvine, CA 92618  
Telephone: (949) 450-1750  
Facsimile: (949) 450-1764

---

CERTIFICATE OF MAILING

I hereby certify that this Transmittal letter, the above-identified documents and papers, and a return postcard are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on November 9, 2000 and is addressed to Box PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231.

Dated: November 9, 2000

By:   
Annette Brooks, Assistant

Express Mail mailing label no. EL636155782US

Case No.: TRNSV-013B

Pat. Appln.

METHODS AND APPARATUS FOR TRANSMYOCARDIAL

5

DIRECT CORONARY REVASCULARIZATION

Field of the Invention

The present invention pertains generally to medical  
treatment methods and devices, and more particularly to  
10 methods and devices for transluminal direct coronary  
revascularization.

Related Applications

This patent application is a continuation-in-part of  
15 co-pending United States Patents Applications 08/730,327,  
filed October 11, 1996, 08/730,496 filed October 11,  
1996, and 08/837,295 filed April 11, 1997 the entire  
disclosure of each such related application being  
expressly incorporated herein by reference.

20

Background of the Invention

i. Coronary Artery Disease

Coronary artery disease continues to be one of the  
leading causes of morbidity and mortality, throughout the  
25 world. The typical etiology of coronary artery disease  
is characterized by the build-up of atherosclerotic  
plaque within the coronary arteries. Such deposits of  
atherosclerotic plaque tend to fully or partially block  
the flow of blood through the affected coronary arteries,  
30 and if untreated can result in myocardial ischemia,  
infarction and death.

For many years, the traditional surgical treatment  
of coronary artery disease has been coronary artery  
bypass surgery. In traditional coronary artery bypass  
35 surgery, the patient is generally anesthetized and placed  
on

cardiopulmonary bypass. A thoracotomy is performed and the obstructed coronary blood vessels are exposed by surgical dissection. One or more segments of the patient's saphenous vein or internal mammary artery is/are harvested for use as bypass graft(s). The harvested segment(s) of vein or artery is/are then anastomosed to the obstructed coronary artery(ies) to form bypass conduit(s) around the arterial obstruction(s). Such traditional coronary artery bypass surgery is expensive, extremely invasive, and is associated with significant operative and perioperative complications.

One alternative to traditional coronary artery bypass surgery is balloon angioplasty. In balloon angioplasty, a flexible guide catheter is percutaneously inserted into a peripheral artery (e.g., the femoral artery) and is transluminally advanced through the vasculature until the distal tip of the catheter is within an obstructed coronary artery. Thereafter, a balloon catheter is passed through the guide catheter and into the obstructive lesion. The balloon of the balloon catheter is inflated one or more times to dilate coronary artery in the region of the obstructive lesion. These balloon angioplasty procedures tend to be less expensive and less traumatic than traditional coronary artery bypass surgery. However, balloon angioplasty procedures of this type have been associated with a significant incidence of restenosis at the angioplasty site. The cause and mechanism of such restenosis continues to be the subject of ongoing study. However, such restenosis has generally been attributed to either a) an increase in the mass of the artery wall (e.g., neointima formation), b) a thickening of the artery wall without substantial change in it's mass (e.g., vascular remodeling) and/or c) radial contraction of the balloon-dilated artery wall upon healing of cracks and fissures that have been created by the balloon dilation process.

Another alternative to traditional coronary artery bypass surgery is transluminal atherectomy or ablation of the obstructive matter within the coronary artery. These transluminal atherectomy or ablation procedures are performed by passing a catheter-mounted ablation apparatus through the vasculature to the site of the coronary obstruction. the catheter-mounted ablative apparatus is then utilized to cut, shave, sonicate, pulverize or otherwise ablate the obstructive matter from the lumen of the coronary artery. These atherectomy or ablative procedures must be performed with caution to avoid abrasion or damage to the artery wall, as such abrasion or damage can result in excessive scarring and subsequent reclusion of the artery lumen. Furthermore, these atherectomy or ablative procedures may, in some cases at least, be confounded by the need to meticulously contain and remove the severed fragments of obstructive matter in order to prevent such fragments of obstructive matter from escaping into the patient's circulatory system. Examples of such atherectomy catheters and other catheter-mounted ablative apparatus are described in United States Patent Nos. 3,433,226 (Boyd), 3,823,717 (Pohlman, et al.), 4,808,153 (Parisi), 4,936,281 (Stasz), 3,565,062 (Kuris), 4,924,863 (Sterzer), 4B70,953 (Don Michael, et al.), 5,069,664 (Suess, et al.), 4,920,954 (Alliger, et al.) and 5,100,423 (Fearnot), as well as foreign patents/patent publications EP0347098A2 (Shiber), WO87-05739 (Cooper), WO89-06515 (Bernstein, et al.), WO90-0130 (Sonic Needle Corp.), EP316789 (Don Michael, et al.), DE '3,821,836 (Schubert), DE2438648 (Pohlman), and EP 0443256A1 (Baruch).

Other alternatives to traditional coronary artery bypass surgery have included minimally invasive endoscopic procedures which, ostensibly at least, can be performed through small (e.g., 1-3cm) incisions formed in the patient's chest wall, by insertion of a thoracoscope

and associated operative instruments through such incisions. One such thoracoscopic coronary bypass procedure is described in United States Patent No. 5,452,733 (Sterman et al.). If perfected, these minimally invasive coronary artery bypass procedures may lessen the discomfort and length of recovery time experienced by patients who undergo such minimally invasive procedures vis a vis those who undergo traditional coronary artery bypass surgery. However, the performance of endoscopic surgical procedures of this type typically requires a great deal of operator skill and training. Furthermore, as with traditional coronary artery bypass surgery, the patients on whom these thoracoscopic procedures are performed are likely to undergo general anesthesia (with or without cardiopulmonary bypass) and the creation of a pneumothorax due to the formation of full-thickness incision(s) in the chest wall. Thus, many of the drawbacks associated with traditional coronary artery bypass surgery, are also associated with these minimally invasive thoracoscopic procedures.

ii. Transmyocardial Revascularization

Another type of procedure which has been devised for improving blood flow to ischemic regions of the myocardium is known as transmyocardial revascularization (TMR). These TMR procedures generally involve the formation of tunnels or passageways through the myocardial muscle for the purpose of providing improved blood flow. In one such TMR procedure, a tissue-boring device, such as a laser, is utilized to form a series of small-diameter passageways from the epicardial surface of the heart, through the myocardium, and into the left ventricle. Jeevanandam, et al., *Myocardial Revascularization By Laser-Induced Channels*, Surgical Forum XLI, 225-227 (Oct. 1990); also see, U.S. Patent No. 4,658,817 (Hardy).

A variant of the above-described TMR procedure is described in United States Patent No. 5,389,096, (Aita, et al.), wherein a catheter-mounted tissue-boring apparatus (e.g., a laser) is advanced into a chamber  
5 (i.e., left ventricle) of the heart and is used to form a plurality of blind, partial-thickness passageways from the chamber of the heart into the myocardium.

Modified TMR procedures have also been described wherein an internally valved transmyocardial passageway  
10 is formed between a coronary artery and the left ventricle of the heart, such that blood from left ventricle may flow into the coronary artery. These modified TMR procedures, hereinafter generally referred to as "Transmyocardial Direct Coronary Revascularization"  
15 (TMDCR), are described in United States Patent Nos. 5,287,861 (Wilk), 5,409,019 (Wilk), and 5,429,114 (Wilk). At least some of these TMDCR methods require that a catheter be introduced into the obstructed coronary artery and advanced through the obstructive  
20 lesion. After the catheter has been advanced through the obstructive lesion, the distal tip of the catheter is stirred or bent toward the artery wall and a tissue-penetrating element is passed through the artery wall, through the adjacent myocardium, and into the chamber of  
25 the left ventricle. Also, in this previously described TMDCR method, a stent or valving apparatus is required to be positioned within the transmyocardial passageway to perform a one-way valving function (i.e., to open and close the transmyocardial passageway in accordance with  
30 changes in the systolic-diastolic cardiac cycle).

These TMDCR methods, previously described in United States Patent Nos. 5,287,861 (Wilk), 5,409,019 (Wilk) and 5,429,114 (Wilk), may be difficult or impossible to perform in patients who suffer from total or near total  
35 obstructions of a coronary artery, because of the necessary for advancing the catheter through the coronary artery obstruction to accomplish creation of the



transmyocardial passageway at a location which is downstream of the coronary obstruction. Furthermore, because these previously described TMDCR methods require placement of a stent within the transmyocardial passageway, such procedures are necessarily associated with procedural complexities associated with measuring and pre-cutting the stent to a precise length so that it fits within the transmyocardial passageway without protruding into the chamber of the left ventricle and/or the lumen of the coronary artery. Also, any stent which is positioned solely within the transmyocardial passageway may be subject to repetitive flexing and/or stressing as the myocardium undergoes its normal contraction and relaxation. Such repeated flexing and/or stressing of the intramyocardial stent may lead to unwanted migration, dislodgement or damage of the stent.

iii. Intermittent Coronary Sinus Occlusion For Coronary Retroperfusion

Yet another procedure which has been proposed as a means for treating acute myocardial ischemia is known as intermittent coronary sinus occlusion (ICSO). In many if not all ICSO procedures, the inflatable balloon is placed in the coronary sinus and is attached to a mechanical pump. The mechanical pump operates to intermittently inflate and deflate the balloon so as to intermittently occlude the coronary sinus. Such intermittent inflation and deflation of the balloon may be linked to the coronary sinus pressure so as to optimize the retroperfusion of the ischemic myocardium. Specific ICSO procedures have been described in Belamy, R.F. (et al.) *Effect of Coronary Sinus Occlusion on Coronary Pressure-Flow Relations*, Am. J. Physiol. 239 (Heart Circ. Physiol. 8) HS 57-HS64, 1980; Pantely, G.A. (et al.) *Effect of Resistance, And Zero Flow Pressure During Maximum Vasodilation in Swine*, Cardiovascular Research, 22:79-86, 1988.

Because the coronary sinus balloon is typically mounted on a percutaneously inserted catheter and is connected to an extracorporeally located pumping system, the clinical usefulness of these ICSO procedures is presently limited to temporary applications intended to minimize heart muscle damage following infarction or during acute periods of myocardial ischemia. However, the general concept of these ICSO procedures could be applicable for the long-term treatment of chronic myocardial ischemia if a totally indwelling system could be devised which would eliminate the need for continued coronary sinus catheterization and/or the deployment of an extracorporeal pumping apparatus connected to such catheter.

When considering the manner in which the ICSO procedures operate, it is helpful to bear in mind that the human circulatory system functions to send oxygenated blood from the aorta to the heart muscle (myocardium) via the left and right coronary arteries (small and large arteries). Following the oxygen/metabolite exchange in the myocardium, the venous system returns the de-oxygenated blood via the epicardial veins (large and small veins). A small fraction of the de-oxygenated blood returns through a set of small vessels which empty directly into the chambers of the heart called the Thebesian veins. Support exists in clinical literature that these Thebesian vessels can carry as much as 90 percent of the total coronary inflow back into the chambers of the heart. The Thebesian vessels connect to both the venous and arterial beds in an interface at the capillary level. Based upon this knowledge of heart function, researchers have suggested that occluding the venous system (e.g. blocking the coronary sinus or other large vein), does not compromise heart function and may in fact create a beneficial effect in cases of diseased or ischemic myocardium.

One particular type of ICSO procedure, known as pressure-controlled intermittent coronary sinus occlusion (PICSO), and apparatus for performing such procedure are described in European Patent Application No. EP0230996 to Mohl. In this

PICSO procedure, an external balloon catheter is inflated in the coronary sinus for a period of time (several cardiac cycles). This PICSO procedure is typically performed in a hospital setting, during a coronary catheterization procedure.

- 5 This PICSO procedure has been shown to elevate the pressure in the venous bed, providing a therapeutic benefit. (see, Mohl, The Development and Rationale of Pressure Controlled Intermittent Coronary Sinus Occlusion - A New Approach to Protect Ischemic Myocardium, Wiener klinische Wochenschrift, pp 20-25, January 6, 1984; also see, Moser, Optimization of Pressure Controlled Intermittent Coronary Sinus Occlusion Intervals by Density Measurements, in *The Coronary Sinus*, Eds. Mohl, Wolner, Glogar, Darmstadt: Steinkopff Verlag, 1984 pp. 529-536; Schreiner, The Role of Intramyocardial Pressure During Coronary Sinus Interventions: A Computer Model Study, IEEE Transactions on Biomedical Engineering, Vol. 37, No. 10, October (1990). In addition, research has shown that, in patients who suffer from occlusive coronary artery disease, venous occlusion may actually prevent or reduce the size of a subsequent infarct (heart attack). (Kralios, Protective Effect of Coronary Sinus Obstruction from Primary Ischemia-Induced Ventricular Fibrillation in the Dog, Am. Heart J (1993) 125:987; Lazar, Reduction of Infarct Size With Coronary Venous Retroperfusion, Circulation (1992) 86:II 352).
- 10  
15  
20  
25

- 25 There currently exists a need to provide minimally invasive methods and devices which have the capability of achieving therapeutic effects similar to those of the above-described PICSO procedure of the prior art, but which do not require continuing cardiac catheterization of the patient in order for the beneficial effects of the procedure to remain. Accordingly, it is the object of the present invention to describe various devices that can be implanted percutaneously in the patient's coronary sinus or great cardiac vein where they remain implanted to achieve partial or total occlusion of the coronary venous system. One mechanism of the therapeutic benefits seen clinically are understood to be based upon the slowing of the arterial flow and subsequently the increased the dwell time of the blood in the capillary bed allowing for
- 30  
35

an increased oxygen-metabolite exchange. The benefits of this phenomenon are better oxygen uptake and potentially a decrease in the infarct size in the event of a future cardiac arrest, and/or potentially global ischemic protection.

5 Another mechanism providing potential benefit is the resultant redistribution of flow through collateral capillary beds, allowing perfusion of regions of the heart that may be otherwise ischemic (lack of perfusion of blood flow due to disease in vessels feeding those regions). In addition,  
10 angiogenesis, a stimulation of the endothelial cells lining the internal walls of vessels to form new blood vessels, may be stimulated as a compensatory mechanism in response to the disruption of normal venous blood flow, thereby providing additional myocardial perfusion through newly created blood  
15 flow conduits.

In view of the above-summarized shortcomings and complexities of the previously described TMDCR methods, there exists a need in the art for the development of  
20 improved TMDCR methods and associated apparatus which may be utilized without the need for cumbersome stenting of the transmyocardial passageway and/or implantation of one-way valving apparatus within the transmyocardial passageway. Also, there exists a need for the  
25 development of a new TMDCR methods which can be performed in patients who suffer from total or near total coronary artery occlusion(s), without the need for advancing a catheter through such coronary artery occlusion(s).

#### Summary of the Invention

30 The present invention provides new TMDCR methods, as well as certain valving devices which are usable in conjunction with these TMDCR methods.

i. TMDCR Procedures Wherein Transmyocardial Passageway Is Formed Between a Chamber of the Heart and a  
35 Coronary Vein

In accordance with the present invention, there is provided a specific TMDCR method wherein a

transmyocardial passageway is formed between a chamber of the heart (e.g., left ventricle) and a coronary vein. In this embodiment of the invention, blood may pass from the cardiac chamber, through the transmyocardial passageway, and into the coronary vein for the purpose of improving blood flow to the myocardium and/or to equalize or normalize pressures within the coronary venous vasculature by draining blood from the vein into the cardiac chamber. The coronary vein of this embodiment may be situated next to an obstructed coronary artery, and one or more secondary blood flow passageways may be created between the coronary vein and the adjacent artery, at site(s) which is/are downstream of the coronary artery obstruction. Also, the lumen(s) of the coronary vein and/or adjacent coronary artery may be blocked or embolized at appropriate positions to facilitate the flow of blood in the desired direction(s) through the man-made blood flow passageway(s), the coronary vein and/or the coronary artery. Additionally, one or more valving apparatus may be positioned within the coronary vein and/or within the cardiac chamber, to control or intermittently block the flow of blood through the transmyocardial passageway.

ii. TMDCR Procedures Wherein Temporary A-V Fistula is Used to Facilitate Formation of Transmyocardial Passageway Entering Coronary Artery Downstream of Obstruction or Other Intravascular Procedure

Further in accordance with the present invention, there are provided TMDCR procedures wherein a transmyocardial passageway-forming catheter is initially advanced into a coronary vein which lies adjacent to an obstructed coronary artery. The passageway forming catheter is advanced through the coronary vein until the distal end of the catheter is adjacent a location on the coronary artery which is downstream of the coronary artery obstruction. Thereafter, the passageway-forming catheter is utilized to form an arterio-venous passageway

which extends from the coronary vein wherein the catheter is located into the coronary artery, at a site downstream of the obstruction. Thereafter, the passageway-forming catheter is advanced through the arterio-venous passageway and into the coronary artery. The passageway-forming catheter is then oriented such that the tissue-penetrating element of the catheter will pass out of the catheter, through the wall of the artery and into a chamber of the heart (e.g., left ventricle). Thereafter, the tissue-penetrating catheter is removed and the arterio-venous passageway, which had been initially formed to allow the passageway-forming catheter to enter the coronary artery downstream of the obstruction, is closed by way of an occlusion apparatus, sutures, cautery, adhesive, or any other suitable tissue closure method or apparatus. Thus, by this procedure, a transmyocardial passageway is formed between a chamber of the heart (e.g., left ventricle) and an obstructed coronary artery, at a site downstream of the coronary artery obstruction, without the need for advancing any guidewire, catheter or other apparatus through the obstruction located within the coronary artery.

The temporary arteriovenous fistula created in this procedure may also be used for other purposes, such as to perform an atherectomy within the lumen of the occluded vessel, or to place a guidance/aiming apparatus (e.g., a target or signal-emitting apparatus) within the lumen of the occluded artery downstream of the obstruction to facilitate formation of a transmyocardial or interstitial passageway into the occluded blood vessel, downstream of the obstruction. This aspect of the invention will be particularly useful in patients in whom the obstruction is sufficiently complete as to prevent a catheter from being passed through the obstruction, but in whom it is desirable to catheterize the distal portion of the occluded blood vessel downstream of the obstruction to accomplish a therapeutic procedure (e.g., atherectomy,

ablation of the occlusive matter, placement of a target, etc.)

iii. Other Procedures Using The Temporary A-V Fistula

Further in accordance with the invention, a  
5 temporary arterio-venous fistula of the above-described  
type may be utilized to facilitate the performance of  
other therapeutic or interventional procedures within the  
lumen of a blood vessel, downstream of an occlusion.  
This aspect of the invention will be particularly  
10 applicable in patients who have total or near total  
occlusions of an artery, and in whom it would be  
difficult or impossible to advance a catheter through the  
total or near total occlusion.

The types of interventional or therapeutic  
15 procedures which may be performed through the temporary  
arterio-venous fistula include, but are not necessarily  
limited to, balloon angioplasty, atherectomy, stenting,  
thrombolysis, full or partial ablation or removal of  
occlusive matter, or installation of an apparatus (e.g.,  
20 a signal-emitting target) into the lumen of the blood  
vessel, downstream of the obstruction.

This aspect of the invention may be particularly  
useful in patients who have previously undergone coronary  
artery bypass surgery such that a bypass graft is  
25 anastomosis to a coronary artery, downstream of a total  
or near total obstruction. In those patients, it is not  
unusual for a secondary obstruction to form immediately  
downstream of the anastomosis of the bypass graft. In  
the event that such secondary obstruction does form, the  
30 temporary arterio-venous fistula of the present invention  
may be used to permit an interventional apparatus (e.g.,  
balloon angioplasty catheter, thrombolysis catheter,  
atherectomy catheter, ablation catheter, stent-delivery  
catheter, etc.) into the lumen of the coronary artery,  
35 downstream of the obstruction, to treat the secondary  
obstruction which has formed adjacent the anastomosis.  
After such therapeutic or interventional procedure has

been completed, the temporary arterio-venous fistula may be closed by the above-described procedure, thereby restoring pathency to the segment of the artery downstream of the bypass graft anastomosis.

5    iv.    TMDCR Procedures Using Unstented Transmyocardial Passageway

Further in accordance with the present invention, there is provided a method for coronary re-vascularization wherein an *unstented* transmyocardial  
10    passageway (e.g., a puncture tract, bore, tunnel, or other passageway) is formed between a chamber of the heart (e.g., the left ventricle) and a coronary vessel (e.g., a) an endogenous coronary artery; b) an endogenous coronary vein; c) a man-made passageway which has been  
15    formed in the heart, and which leads to an endogenous coronary vein; d) a man-made passageway which has been formed in the heart, and which leads to an endogenous coronary artery; and/or e) a man-made passageway which has been formed in the heart between an endogenous  
20    coronary artery and an endogenous coronary vein). The unstented transmyocardial passageway(s) created in accordance with this embodiment of the invention may be utilized to improve perfusion of the myocardium by shunting blood from the chamber of the heart (e.g., left  
25    ventricle) into the coronary vessel (e.g., vein artery or man-made passageway), or may alternatively be utilized to equalize or normalize flow or pressure within the cardiac vasculature by draining blood from one or more cardiac vessels (e.g., vein, artery or man-made passageway), into  
30    the chamber of the heart.

v.    Valving Devices Positionable in Coronary Vessels

Still further in accordance with the present invention, there are provided several types of intraluminal valving apparatus which may be positioned  
35    within the lumen(s) of the coronary blood vessel(s) (i.e., artery, vein or man-made passageway) which intersect with the transmyocardial passageway, to



intermittently block bloodflow, in at least one direction, through the transmyocardial passageway. These intraluminal valving devices generally comprise tubular bodies having at least one occluder member positioned therein, said occluder member(s) being alternately moveable between i) open position(s) whereby bloodflow is permitted to pass through the transmyocardial bloodflow passageway in a desired direction, and ii) closed position(s) whereby blood is prevented from flowing through the transmyocardial bloodflow passageway, in an undesired direction.

**vi. Tissue Valves For TMDCR Passageway**

Alternatively, the present invention also includes endogenous tissue valve(s) which are formed in the transmyocardial passageway to perform a desired one-way valving function whereby blood is permitted to flow through the transmyocardial bloodflow passageway in a first direction, but is prevented from backflowing or regurgitating in a second direction.

**vii. Intracardiac Valving Devices For TMDCR Passageway**

Still further in accordance with the present invention, there are provided intracardiac valving devices which are mountable within a chamber of the heart (e.g., left ventricle) immediately adjacent to an opening into a transmyocardial passageway which extends from the cardiac chamber to a coronary vessel (e.g., artery, vein or man-made passageway). Such intracardiac valving device may be constructed such that it will open in response to hemodynamic pressure generated during systole and/or in response to mechanical contraction (i.e., shortening and thickening) of the myocardium during systole. When open, the intracardiac valving device permits blood to flow through the transmyocardial bloodflow passageway. Thereafter, the valving device may be constructed to close when diastolic pressures are present in the cardiac chamber or when the myocardium undergoes mechanical relaxation (i.e., lengthening and

thinning during diastole. When closed, the valving device will prevent blood from backflowing or regurgitating from the transmyocardial bloodflow passageway, into the cardiac chamber.

5 viii. Protrusive Stents and Stented Grafts For TMDCR Passageways

Still further in accordance with the present invention, there are provided stents and stented grafts which are positionable within the transmyocardial  
10 passageway, and which protrude into the adjacent coronary vessel (e.g., vein, artery or man-made passageway). These protrusive stents and/or protrusive stented grafts may be self-expanding or pressure-expandable. Optionally, one or more valves or occluder members may be  
15 positioned within such protrusive stents and/or stented grafts to facilitate valving or directed movement of bloodflow in accordance with the diastolic/systolic cardiac cycle.

ix. Intravascular Valving Apparatus and Methods for Intermittent Coronary Venous Occlusion  
20

Still further in accordance with the present invention, there are provided intravascular valving devices which are positionable within the coronary sinus, great cardiac vein or other areas of the coronary venous  
25 vasculature to control the back pressure within one or more coronary veins in a manner which will result in increased dwell time of the arterial blood within the capillary bed of the ischemic myocardium, and/or dilation of the capillary bed, thereby improving perfusion of the  
30 ischemic region(s) of the myocardium.

These intravascular valving devices may generally comprise a radially expandable cylindrical frame having one or more leaflets or other occluding members (e.g., ball-in-cage type check valve, etc.) which are  
35 specifically configured and constructed to prevent venous outflow until the pressure within the coronary sinus, great cardiac vein or other coronary vein exceeds a

predetermined amount. Optionally, one or more transmyocardial passageways may be formed between the coronary vein(s) and/or coronary artery(s) to provide additional blood flow into the coronary vasculature in conjunction with the increased back pressure created by this intravascular valving apparatus. Alternatively or additionally, these intravascular valving apparatus of the present invention may be implanted within the coronary sinus, great cardiac vein, or other coronary vein to regulate coronary venous pressure in conjunction with an interstitial arterio-venous passageway or passageway formed between a chamber of the heart and a coronary vein, in accordance with the procedures previously described in applicant's United States Patent Applications Serial Nos. 08/730,327 and 08/730,496, filed on October 11, 1996. The tissue penetrating member will reside when varying lengths of said tissue penetrating member have been advanced out of the catheter, said imaging means being thereby useable to focus on a selected one of said distance indicia to optimally position the catheter to form the desired passageway.

Optionally, these intravascular valving apparatus may incorporate one or more of the following additional features:

- The valving apparatus may be puncturable or traversable so as to permit a catheter to be passed through the valving apparatus in the event that such catheter passage becomes necessary at a later time;
- The valving apparatus may be removable such that it may be rescued and removed from the body in the event it is no longer necessary, or if removal becomes desirable for some other reason;
- The valving apparatus may be provided with projections, hooks, material for tissue in growth, or other suitable anchoring apparatus to assist in

holding the valving apparatus in its desired position within the venus lumen; and

• The valving apparatus may be formed of radiologically imagable material, or may be provided with one or more radio dense or radio opaque markers to facilitate visualization of the valving apparatus by x-ray or fluoroscopy.

These intravascular valving apparatus of the present invention are implantable within the coronary sinus, great cardiac vein or other coronary vein, and will remain indwelling so as to regulate back pressure within the system and/or to improve myocardial perfusion, on an ongoing basis, without the need for continued placement of a catheter-mounted counterpulsation balloon within the coronary sinus and/or deployment of any extracorporeal instrumentation, such as the extracorporeal pumping apparatus which has been traditionally required for intermittent inflation and deflation of the coronary sinus counterpulsation balloon.

Further objects and advantages of the present invention will become apparent to those skilled in the art upon reading and understanding of the following detailed descriptions of preferred embodiments.

#### Brief Description of the Drawings

Figure 1 is a perspective view of a human heart showing the typical anatomical positioning of the coronary arteries and coronary veins of the left heart.

Figure 1a is a partial cut-away sectional view of a human heart wherein a transmyocardial passageway has been created between the left ventricle and a coronary vein, in accordance with the present invention.

Figure 1b is a partial longitudinal sectional view through an obstructed coronary artery and adjacent coronary vein, showing a transmyocardial passageway of the present invention, extending between the chamber of the left ventricle and the coronary vein.

Figure 1c is a partial longitudinal sectional view through an obstructed coronary artery and adjacent coronary vein, showing a transmyocardial passageway of the present invention extending between the chamber of the left ventricle to the coronary vein, and a secondary bloodflow passageway extending from the coronary vein to the adjacent coronary artery, downstream of the obstruction.

Figure 1d is a partial longitudinal sectional view through a portion of the myocardium of a human heart, adjacent the left ventricle, showing an alternative embodiment of the present invention wherein a transmyocardial bloodflow passageway extends from the chamber of the left ventricle to a secondary passageway which has been created between the obstructed coronary artery and the adjacent coronary vein.

Figure 2 is a longitudinal sectional view showing a first embodiment of an intravascular valving apparatus of the present invention operatively positioned within a coronary blood vessel (artery, vein or man-made passageway).

Figure 2a is a perspective view of the intravascular valving apparatus of Figure 2.

Figure 2b is an elevational view of a variant of the intravascular valving apparatus shown in Figures 2 and 2a, wherein a bloodflow blocking bulkhead is formed on the upstream end of the apparatus.

Figure 3 is a longitudinal sectional view of a second embodiment of an intravascular valving apparatus of the present invention operatively positioned in a coronary blood vessel (artery, vein or man-made passageway).

Figure 3a is longitudinal sectional view showing variant of the second intravascular valving apparatus embodiment shown in Figure 3, wherein two (2) separate valving apparatus are respectively positioned upstream and downstream of the junction between the

transmyocardial bloodflow passageway and the coronary blood vessel (artery, vein or man-made passageway).

Figure 3b is a longitudinal sectional view of another variant of the second intravascular valving apparatus embodiment shown in Figure 3, wherein three (3) valves are incorporated within a single tubular body to accomplish valving of bloodflow through a transmyocardial bloodflow passageway and coronary blood vessel (artery, vein or man-made passageway).

Figure 4 is a longitudinal sectional view showing a third embodiment of an intravascular valving apparatus of the present invention operatively positioned within a coronary blood vessel (artery, vein or man-made passageway).

Figure 5 is a longitudinal sectional view showing an intracardiac valving apparatus of the present invention along with an optional retainer assembly (dotted lines) useable to mount such intracardiac valving apparatus on the inner wall of the heart.

Figure 5a is a perspective view of the intracardiac valving apparatus of Figure 4 having the optional retainer assembly affixed thereto.

Figures 6a and 6b are longitudinal sectional views of a human heart wherein a bloodflow passageway has been created between the left ventricle and a coronary blood vessel (artery, vein or man-made passageway), and a valving tissue valve has been created in the wall of the blood vessel, in accordance with the present invention.

Figures 7a-7b are longitudinal sectional views of a human heart wherein a blood vessel passageway has been created between the left ventricle and a coronary blood vessel (artery, vein or man-made passageway), and wherein an elastic suture has been positioned, in accordance with the present invention.

Figure 8a is a longitudinal sectional view showing a protrusive stent apparatus of the present invention implanted within a transmyocardial passageway and

extending into a coronary blood vessel (e.g., artery, vein or man-made passageway).

Figure 8b is a longitudinal sectional view showing an alternative embodiment of the protrusive stent apparatus shown in Figure 5a.

Figure 8c is a longitudinal sectional view showing another alternative embodiment of the protrusive stent apparatus shown in Figure 5a, having an optional tubular covering and/or optional valve(s) incorporated therein.

10           Figure 9 is a partial sectional view of a portion of  
a mammalian heart wherein an intravascular valving  
apparatus has been positioned within a coronary vein to  
provide pressure-controlled intermittent coronary venous  
occlusion for enhanced coronary retroperfusion.

15           Figure 9a is a perspective view of the intravascular  
valving apparatus shown in Figure 9.

Figure 9b is a graph of coronary venous pressure vs. time in a coronary vein having an intravascular valving apparatus of the present invention implanted therein.

20 Figure 9c is a draft of coronary venous pressure vs.  
flow in a coronary vein having an intravascular valving  
apparatus of the present invention implanted therein.

Figure 10 is a partial longitudinal section view through a portion of a mammalian heart showing a passageway-forming catheter device of the present invention being used to form a transmyocardial passageway from a chamber of the heart, into a coronary blood vessel.

Figure 11a is a partial section view through a portion of a mammalian heart showing the first stage of a transluminal coronary revascularization procedure wherein a temporary arterio-venous fistula is used to pass a passageway forming catheter into an obstructed coronary artery, downstream of the obstruction.

35        Figure 11b is a longitudinal sectional view of a  
portion of a mammalian heart following completion of the  
procedure shown in Figure 11a.

Figure 12a is a shematic diagram of the flow of blood through the coronary vasculature without full or partial blocking of venous return in accordance with the present invention.

5        Figure 12b is a shematic diagram of the flow of blood through the coronary vasculature with full or partial blocking of venous return in accordance with the present invention.

10        Figure 13a is an elevational view of one embodiment of a coronay vein blocking device of the present invention having an optional end cap (dotted lines) disposed on the closed end thereof.

Figure 13b is a cross sectional view through line 13b-13b of Figure 13a.

15        Figure 13c is an elevational view of the membrane covering and optional end cap (dotted lines) of the blocker device of Figure 13a.

20        Figure 13d is an elevational view of the radially expandable wire frame of the blocker device of Figure 13a.

Figures 14a-14c are shematic, staged showings of the operation of a full-occlusion pressure delay valve of the present invention which utilizes an annular balloon filled w/ viscous fluid as the occluder member.

25        Figures 14a'-14b' are shematic, staged showings of the operation of a partial-occlusion pressure delay valve of the present invention which utilizes an annular balloon filled w/ viscous fluid as the occluder member.

30        Figure 15 is a shematic diagram of an implantable magnetic delay valve of the present invention in its closed position.

Figure 16 is a shematic diagram of an implantable oxygen sensor delay valve of the present invention.

35        Figure 16a is a cross sectional view through line 16a-16a of figure 16.



Figure 17 is a graph of valve position vs. capillary pressure for any of the time delayed venous occlusion valves of the present invention.

Figure 18a is a schematic showing of a full-occlusion pressure delay valve of the present invention in its closed position.

Figure 18b is a schematic showing of a full-occlusion pressure delay valve of the present invention in its open position.

Figure 19a is a schematic showing of a partial-occlusion pressure delay valve of the present invention in its closed position.

Figure 19b is a schematic showing of a partial-occlusion pressure delay valve of the present invention in its open position.

Detailed Description of the Preferred Embodiments

The following detailed description and the accompanying drawings are provided for purposes of describing and illustrating presently preferred embodiments of the invention only, and are not intended to limit the scope of the invention in any way.

Upon making reference to the accompanying figures, it will be noted that many of the figures include showings of human cardiovascular anatomy. The various anatomical structures shown in the figures are labeled in accordance with the following legend:

AO . . . . .	Aorta
CBV . . . . .	Coronary Blood Vessel
	(artery, vein or
	man-made passageway)
CA . . . . .	Coronary Artery
CAL . . . . .	Coronary Artery Lumen
CV . . . . .	Coronary Vein
CVL . . . . .	Coronary Vein Lumen
IVC . . . . .	Inferior Vena Cava
SVC . . . . .	Superior Vena Cava
LV . . . . .	Left Ventricle

RV . . . . . Right Ventricle  
IVS . . . . . Intraventricular Septum  
M . . . . . Myocardium

5 I. TMDCR Method Wherein Transmyocardial Passageway is  
Formed Between a Chamber of the Heart and a Coronary  
Vein

With reference to Figures 1-4, the present invention  
includes methods for improving perfusion of regions of  
10 the myocardium M which are ischemic or otherwise affected  
by the existence of an obstruction OB within a coronary  
artery CA, by forming a transmyocardial passageway 10  
which extends from a chamber of the heart, (e.g., left  
ventricle LV), to a coronary vein CV.

15 In some embodiments of this method, the transmyo-  
cardial passageway 10 will simply provide a flow of blood  
from the chamber of the heart and into the coronary vein  
CV, such that the blood will pass in retrograde fashion  
through the coronary vein CV to perfuse the ischemic  
20 portion of the myocardium through the coronary vein, as  
sheen in Figure 1b.

In other embodiments of the invention, a secondary  
bloodflow passageway 12 may be created between the  
coronary vein CV into which the transmyocardial  
25 passageway 10 extends and the obstructed coronary artery  
CA, at a location which is downstream of the obstruction  
OB, as shown in Figure 1c. The formation of this  
secondary bloodflow passageway 12 allows blood from the  
chamber of the heart (e.g., the left ventricle LV) to  
30 initially flow through the transmyocardial passageway 10,  
through a segment of the coronary vein lumen CVL, through  
the secondary bloodflow passageway 12, and into the  
coronary artery lumen CAL, at a location downstream of  
the coronary artery obstruction OB, as shown in Figure  
35 2b. The secondary bloodflow passageway 12 which extends  
between the coronary vein CV and the coronary artery CA  
may optionally be stented or internally supported by a

00607 " 222460

otherwise closed) thereby preventing subsequent passage of blood between the coronary vein CV and coronary artery CA. In this manner, as shown in Figure 11b, this procedure of the present invention results in the formation of a transmyocardial passageway 10 between the left ventricle LV and a coronary artery CA, such that blood may pass from the left ventricle LV, through the transmyocardial passageway 10 and into the lumen of the coronary artery CA, downstream of the obstruction OB. The passage of the tissue-penetrating catheter 100 in the manner described hereabove and shown in Figure 11a eliminates any necessity for advancing the catheter through the obstruction, and avoids the potential dislodgement of portions or particles of the obstruction OB into the coronary circulation.

It will be appreciated that any type of cauterizing, fusing, suturing or blocking apparatus may be used to close off the arterio-venous passageway 104, including at least some of the blocking devices described in applicant's above cited previously filed applications.

### III. Other Procedures Which May Be Performed Using the Temporary A-V Passageway

It will be appreciated those skilled in the art that the temporary arterio-venous passageway 104 described hereabove in Section ii. May also be used for various other therapeutic or interventional procedures wherein it is desirable to gain access to the lumen of a blood vessel, downstream of an occlusion. This temporary arterio-venous passageway 104 is particularly suitable for use in procedures wherein a total or near total occlusion is present in the blood vessel so as to render it difficult or impossible to pass a catheter through the occlusion. The types of therapeutic or interventional procedures which may be performed through the temporary arterio-venous passageway 104 include, but are not necessarily limited to, balloon angioplasty, atherectomy, thrombolysis, placement of apparatus (e.g., a signal

emitting target) within the lumen of the blood vessel downstream of the obstruction, or revascularization procedures such as the TMDCR procedure described hereabove.

5 This aspect of the invention may be particularly usable in patients who have previously undergone coronary artery bypass surgery, for bypassing of a total or near total occlusion. In such patients, it is common for new occlusions to occur at sites downstream of the  
10 anastomosis which connects the bypass graft to the occluded artery. IN such patients, it may be desirable to access the portion of the artery downstream of the occlusion to pass a balloon angioplasty catheter, atherectomy catheter, or other interventional device so  
15 as to treat such occlusions which may occur subsequent to performance of bypass surgery.

#### IV. TMDCR Procedures Using Unstented Transmyocardial Passageway

The present invention also includes alternative TMDCR  
20 methods wherein a transmyocardial passageway 10 is formed between a chamber of the heart and a coronary vessel (i.e., a) an endogenous coronary vein, b) an endogenous coronary artery, c) a man-made passageway in the heart which connects to an endogenous coronary vein; d) a man-  
25 made passageway in the heart which connects to an endogenous coronary or e) a man-made passageway which extends between an endogenous coronary artery and an endogenous coronary vein), and such transmyocardial passageway 10 is allowed to remain non-stented (e.g.,  
30 devoid of any stent or internal support member positioned therewith).

The utilization of a non-stented transmyocardial passageway 10 in accordance with this embodiment of the present invention eliminates the need for precise  
35 measurement, pre-cutting to length and insertion of a stent apparatus within the transmyocardial passageway 10, as is required of the previous TMDCR method described in

United States Patent Nos. 5,287,861 (Wilk), 5,409,019 (Wilk) and 5,429,114 (Wilk). When the non-stented transmyocardial passageway 10 of the present invention is intended to provide bloodflow from the chamber of the heart (e.g., left ventricle) into the coronary vessel (e.g., vein, artery or man-made passageway), the non-stented transmyocardial passageway 10 must remain open during systolic contraction of the myocardium. If the non-stented passageway 10 is permitted to substantially occlude or close-off during systolic contraction of the myocardium, such could prevent or deter the desired blood flow from passing through the transmyocardial passageway 10. In this regard, in embodiments of the invention which utilize the non-stented transmyocardial passageway 10, it may be desirable to debulk, core or otherwise enlarge the diameter of the passageway 10 during its formation so as to ensure that the passageway 10 will remain patent and open, even during systolic contraction of the myocardium. Such coring, debulking or other enlargement of the passageway 10 may be accomplished by any suitable means, including the use of a hollow coring needle, laser, electrosurgical probe, or other tissue removing/ablating device capable of debulking and removing tissue so as to create a transmyocardial passageway 10 of the desired diameter.

Also, it will be appreciated that the non-stented transmyocardial passageway preferably should not fill-in with granulation tissue or otherwise close-off as a result of any scarring or healing process of the myocardium. In this regard, the coring, debulking or other enlargement of the non-stented passageway 10 and/or the continuing passage of blood, therethrough, may be sufficient to prevent or deter such scarring or natural closing of the non-stented passageway 10. However, in applications wherein scarring or natural closing of the non-stented passageway 10 is a potential problem, it may be desirable to cauterize, heat, chemically treat or coat

the walls of the non-stented passageway to prevent or deter blocking of such passageway by scarring or ingrowth of the myocardial tissue.

VII. Valving Apparatus Positionable in the Coronary Vessel(s) to Prevent Backflow Into the Transmyocardial Bloodflow Passageway

In many embodiments of the invention, the transmyocardial passageway 10, 10a may function in it's intended manner without the inclusion of any valving apparatus, for intermittently blocking the flow of blood therethrough. However, in at least some applications, it may be desired to prevent the backflow of blood through the transmyocardial passageway 10, 10a during certain phase(s) of the cardiac cycle when the relative hemodynamic pressures would tend to cause such backflow. In this regard, the present invention includes intravascular valving apparatus 20, 30, 31, 33, 40, examples of which are shown in Figures 2-4. These intravascular valving apparatus 20, 20, 31, 33, 40 are positionable within the lumen of the coronary blood vessel CBV (e.g., vein, artery or man-made passageway), and operate to prevent backflow of blood into the transmyocardial bloodflow passageway 10, 10a.

In general, each of the intravascular valving apparatus 20, 30, 31, 33, 40 of the present invention comprise a radially expandable cylindrical or tubular body which is transluminally advanceable into the lumen of the coronary blood vessel CBV (e.g., artery, vein or man-made passageway), and which is then radially expandable so as to become implanted at a location which is adjacent or near to the intersection of that coronary vessel CBV with a transmyocardial bloodflow passageway 10, 10a. The valving apparatus 20, 30, 31, 33, 40 has an axial bore 24, 34, 42 through which blood may pass as it flows through the lumen of the coronary blood vessel CBV or secondary passageway 12 in which the apparatus 20, 30, 31, 33, 40 is positioned. One or more occluder members

26, 36, 46 are formed within the apparatus 20, 30, 31, 33, 40. Such occluder member(s) 26, 36, 46 are alternately moveable between a first (e.g., open) position whereby blood is permitted to flow from the transmyocardial bloodflow passageway into the coronary blood vessel CBV or secondary passageway 12, and a second (e.g., closed) position whereby blood is prevented or deterred from backflowing or regurgitating from the coronary blood vessel CBV or secondary passageway 12, into the transmyocardial bloodflow passageway.

Individual embodiments of the intravascular valving apparatus 20, 30, 31, 33, 40 are described in more detail herebelow. It will be appreciated, however, that each of the intravascular valving apparatus 20, 30, 31, 33, 40 of the present invention offer advantages over the intramyocardial stenting/valving apparatus described in United States Patent Nos. 5,248,861 (Wilk), 5,409,019 (Wilk) and 5,429,144 (Wilk) in that they are operatively situated entirely within the lumen of the coronary blood vessel CBV of secondary passageway 12 and do not extend into the transmyocardial passage way (e.g., the first passageway 10, 10a) which emanates from the chamber (e.g., left ventricle) of the heart. In this regard, the valving apparatus 20, 30, 31, 33, 40 of the present invention do not require precise measurement or precise cutting-to-length, as is purportedly required of the intramyocardial stenting/valving apparatus described in U.S. Patent Nos. 5,248,861 (Wilk), 5,409,019 (Wilk) and 5,429,144 (Wilk).

It is desirable that the valving apparatus 20, 30, 31, 33, 40 of the present invention be initially disposable in a first radially compact diameter which is small enough to be mounted upon or inserted into an intravascular delivery catheter. Such intravascular delivery catheter, having the valving apparatus 20, 30, 31, 33, 40 mounted thereon or therewithin, is transluminally passable through the vasculature and into

the lumen of the coronary blood vessel CBV wherein the apparatus 20, 30, 31, 33, 40 is to be implanted. Thereafter, the apparatus 20, 30, 31, 33, 40 is radially expanded (by self-expansion or pressure-expansion) to a second radially expanded diameter, wherein the outer surface of the apparatus 20, 30, 31, 33, 40 frictionally engages the surrounding wall of the coronary blood vessel CBV such that the apparatus 20, 30, 31, 33, 40 is thereby implanted and retained in a stationary position. When the valving apparatus 20, 30, 31, 33, 40 is so implanted within the coronary blood vessel CBV, blood may flow through the axial bore 24, 34, 42 of the apparatus 20, 30, 31, 33, 40, as described in more detail herebelow. It is to be appreciated that the valving apparatus 20, 30, 31, 33, 40 may be either self-expanding or pressure-expandable. In this regard, if the valving apparatus 20, 30, 31, 33, 40 is "self-expanding", the cylindrical body of the apparatus 20, 30, 31, 33, 40 may be formed of a shape memory alloy or resilient material (e.g., spring metal) which is inherently biased to it's second radially expanded diameter. Alternately, in embodiments wherein the valving apparatus 20, 30, 31, 33, 40 is "pressure-expandable", the cylindrical body of the apparatus 20, 30, 31, 33, 40 may be formed of plastically deformable material which is initially formed it's first radially compact diameter, and which may be pressure deformed to it's second radially expanded diameter by the exertion of outward force from an internally positioned balloon or other radial expansion device.

It is to be further appreciated that the potential useability and applicability of the intravascular valving apparatus 20, 30, 31, 33, 40, 50 described herebelow is not limited only to uses in connection with the improved TMDCR methods of the present invention, but may also be useable as a modification of the previously described TMDCR methods, such as those of United States Patent Nos.



5,287,816 (Wilk), 5,409,019 (Wilk), and 5,429,144 (Wilk).

a. Intravascular Valving Apparatus-First Embodiment:

FIG. 1

Figures 2, 2a and 2b show a first embodiment of an intravascular valving apparatus 20 which is positioned within the lumen of a coronary blood vessel CBV (artery, vein or man-made passageway), at a location which is adjacent it's intersection with the transmyocardial passageway 10. This embodiment of the valving apparatus 20 has a cylindrical body having an axial bore 24 which extends longitudinally therethrough, and a side aperture 22 formed in the sidewall thereof. The side aperture 22 is preferably the same size or larger than the diameter of the adjacent end of the transmyocardial passageway 10, such that blood flowing from the cardiac chamber (e.g., left ventricle LV) through the transmyocardial passageway 10 will pass directly through the side aperture 22 and into the bore 24 of the valving apparatus 20. An occluder member 26, such as a hinged obturator or pliable elastomeric leaflet is affixed to the cylindrical body of the valving apparatus 20, and extends over and substantially blocks the side aperture 22 so as to prevent the flow of blood out of the side aperture 22. The occluder member 26 is alternately moveable between a first position wherein it blocks blood from flowing out of the side aperture 22, and a second position wherein it permits blood to flow into the bore 24 through the side aperture 22.

This first embodiment of the valving apparatus 20 may be implanted in the lumen of the coronary blood vessel CBV such that the side aperture 22 is in alignment with the adjacent end of the bloodflow passageway 10. During systolic contraction of the heart the relatively high pressure within the left ventricle will force the occluder member 26 to its second (open) position, allowing blood to flow from the left ventricle, through the transmyocardial passageway 10, through the side aperture 22, through the bore 24 and into the lumen of

improved bloodflow to an ischemic or blood-flow-deprived region of the myocardium M.

Optionally, secondary occluder members 38 may be formed or mounted within the bore 34 of the apparatus 30, upstream of the side opening 32. These optional secondary occluder members 38 may be of the same type and construction as the above-described downstream occluder members 36. If present, such additional occluder members 38 will assume their first (e.g., closed) position when the pressure of blood within the bore 34 of the apparatus 30 downstream of such secondary occluder members 38 is greater than the pressure of blood within the coronary blood vessel CBV upstream of the such secondary occluder member 38. In this regard, the provision of such secondary occluder members 38 within the apparatus 30 will obviate the need for placement of a proximal occlusion apparatus 14a within the lumen of the coronary blood vessel CBV upstream of the transmyocardial bloodflow passageway 10. The inclusion of such secondary occluder members 38, or the alternative use of a proximal occlusion member 14a, will be of particular importance when the coronary blood vessel CBV is a coronary vein CV, due to the substantial difference between endogenous coronary venous blood pressures and those pressures which will be created by systolic arterial bloodflow through the coronary vein, downstream of the transmyocardial bloodflow passageway 10.

Figure 3a shows one variant of the second embodiment wherein two (2) separate intravascular valving apparatus 31a, 31b are respectively positioned upstream and downstream of the transmyocardial bloodflow passageway. The above-described occluder members 36 are formed in the apparatus 31b which is positioned downstream of the transmyocardial bloodflow passageway 10 and the above-described secondary occluder members 38 are formed within the apparatus 31a which is positioned upstream of the transmyocardial bloodflow passageway 10. In this manner,

these separate intravascular valving apparatus 31a, 31b, will function in the same manner as the apparatus 30 shown in Figure 3, when it is equipped with the optional secondary occluder members 38. However, it will be appreciated that these separate intravascular valving apparatus 31a, 31b do not have any side aperture 32, as does the device shown in Figure 3, and accordingly, will obviate any need for correctly sizing an aligning such side aperture 32 with the transmyocardial bloodflow passageway 10.

Figure 3b shows another variant of the second embodiment wherein a single intravascular valving apparatus 33, in the nature of a tubular stent or tubular body, is provided with three (3) separate valves 26, 36, 38 at locations which are a) at the junction of the transmyocardial passageway 10 and the coronary blood vessel CBV, b) upstream of the transmyocardial passageway 10 and c) downstream of the transmyocardial passageway 10, respectively. These valves 26, 36, 38 may comprise self-sealing pliable slit openings, elastomeric leaflets, hinged occluder members or any other suitable type of structure or apparatus which will intermittently open and close, to permit bloodflow in the desired direction therethrough. For example, in applications wherein it is desired for the transmyocardial passageway 10 to provide a flow of blood from the cardiac chamber into the coronary blood vessel CBV, the first valve 26 will operate to open during systole to permit blood to flow from the transmyocardial passageway 10 into the coronary blood vessel CBV, but will close during diastole to prevent backflow or regurgitation into the cardiac chamber. Similarly, the second (upstream valve 38 will close during systole to prevent backflow of blood through the proximal end opening of the valving apparatus 33. The third (downstream) valve 36 will open during systole to permit the desired flow of blood entering through the transmyocardial passageway 10, to continue on

downstream through the coronary blood vessel CBV in the desired perfusion direction.

c. Intravascular Valving Apparatus-Third Embodiment

Figure 4 shows a third embodiment of the intravascular valving apparatus 40 which comprises a generally cylindrical body having an axial bore 42 extending longitudinally therethrough and a plurality of occluder members 46 formed therewithin. The cylindrical body and occluder members 46 of this third embodiment of the apparatus 40 are the same as those of the above described second embodiment, except that the cylindrical body of this third embodiment is devoid of any side aperture(s) or openings in the cylindrical sidewall. In contrast to the above described second embodiment 30, this third embodiment of the apparatus 40 is implanted in the lumen of the coronary blood vessel CBV at a location which is downstream of the junction between the coronary blood vessel CBV and the first bloodflow passageway 10.

It will be appreciated that the individual features and attributes of each of the above-described embodiments of valving apparatus 20, 30, 31, 33, 40 may be incorporated into any or all of the other above-described valving apparatus 20, 30, 31, 33, 40 as feasible, to accomplish the desired hemodynamic bloodflow within the coronary vasculature.

VI. Intracardiac Valving Apparatus For Controlling Bloodflow Through the Transmyocardial Passageway

Figures 5 and 5a show examples of intracardiac valving apparatus 80 which may be utilized to prevent backflow of blood through the transmyocardial passageway 10, or to otherwise control the flow of blood through the transmyocardial passageway 10 in accordance with the systolic/diastolic cardiac cycle.

As shown, the intracardiac valving apparatus 80 is positionable within the cardiac chamber (e.g., left ventricle) immediately adjacent the opening of the transmyocardial passageway 10 thereinto. The

intracardiac valving apparatus 80 may comprise any suitable type of hinged, pliable or moveable occlusion member or self-sealing slit which will operate to intermittently block or unblock the flow of blood in at least one direction through the transmyocardial passageway 10. In the embodiment shown in Figures 5, 5a, the intracardiac valving apparatus 80 comprises a generally annular body having a central aperture formed therein and an occluder member 81, such as a pliable elastomeric flap, mounted within the aperture. The occluder member 81 will move, in relation to hemodynamic bloodflow and/or contraction of the myocardium M, between an open position whereby blood is permitted to pass in at least one direction through the transmyocardial passageway 10, and a closed position whereby blood is prevented from flowing in at least one direction through the transmyocardial passageway 10.

The intracardiac valving apparatus 80 may be implanted within the cardiac chamber by any suitable surgical or non-surgical technique. Preferably, the intracardiac valving apparatus 80 is initially positioned within or upon a delivery catheter, and the delivery catheter is advanced through the coronary blood vessel CBV, and through the transmyocardial passageway 10. Thereafter, the intracardiac valving apparatus 80 is released or ejected from the delivery catheter, and is caused to radially expand to its operative configuration. the expanded valving apparatus 80 is then retracted into abutting contact with the myocardial wall, as shown.

The intracardiac valving apparatus 80 may be attached to the myocardial wall by any suitable attachment such as hooks, sutures, adhesives or a retaining assembly which is operative to hold the intracardiac valving apparatus 80 in its desired fixed position upon the myocardial wall. One such retaining apparatus, shown in Figures 5 and 5a, comprises an

annular retaining ring 82 which is positionable within the coronary blood vessel CBV and a plurality of elastomeric tether members 84 which extend between the retainer ring 82 and the intracardiac valving apparatus 5 80. In this manner, the elastomeric tethers 84 will resiliently draw the retaining ring 82 and intracardiac valving apparatus 80 toward one another, so as to hold the intracardiac valving apparatus 80 in fixed abutment with the myocardium M as shown.

10 In some embodiments of the intracardiac valving apparatus 80, the occluder member 81 will be designed to move in response to changes in hemodynamic pressure, such that when the hemodynamic pressure within the cardiac chamber (e.g., left ventricle) exceeds that within the transmyocardial passageway 10, the occluder member 81 15 will move to it's open position, and when the pressure within the transmyocardial passageway 10 exceeds that within the cardiac chamber (e.g., left ventricle) the occluder member 81 will move to it's closed position.

20 Alternatively, in other embodiments of the intracardiac valving apparatus 80, the occluder member 81 may be designed to move in relation to contractile changes in the myocardial muscle. In these embodiments, the occluder member 81 will be mechanically linked or 25 coupled to the body of the intracardiac valving apparatus 80 such that, when the myocardium undergoes contraction (e.g., shortening and thickening), the occluder member 81 will be propelled to it's open position, and when the myocardium undergoes relaxation (e.g., lengthening and 30 narrowing) the occluder member 81 will move to it's closed position.

In this manner, the intracardiac valving apparatus 80 of the present invention serves to control the desired bloodflow through the transmyocardial passageway 10, 35 without the need for customizing or precise cutting-to-size of any intramyocardial stent, as has been described in the prior art.

VII. Tissue Valve for Preventing Backflow into the Transmyocardial Bloodflow Passageway

An alternative to the use of the above-described intravascular valving apparatus 20, 30, 31, 33, 40 and/or  
5 the intracardiac valving apparatus 80, is an endogenous tissue valve which may be formed within the transmyocardial passageway 10 or at either end thereof. For example, Figures 6a-6b show an endogenous tissue valve 50 which is formed at the junction of the  
10 transmyocardial bloodflow passageway 10 and a coronary blood vessel CBV (e.g., artery vein or man-made passageway).

With reference to Figure 6a-6b, the endogenous tissue valve 50 may comprise one or more segment(s) 54 of  
15 the wall of the coronary blood vessel CBV, along with one or more tapered segment(s) of underlying myocardial tissue 52.

This endogenous tissue valve 50 is formed such that the segment(s) of blood vessel wall 54 and underlying  
20 portion(s) of myocardial tissue 52 will receive sufficient blood supply so as not to become necrotic or infarcted. The thickness and mass of the tissue valve 50 is preferably defined so that, when the heart undergoes systolic contraction the elevated pressure created within  
25 the left ventricle LV and transmyocardial bloodflow passageway 10 will force the tissue valve 50 to an open position, as illustrated in Figure 5a, thereby creating an opening 56 through which blood may flow into the lumen of the coronary blood vessel CBV, in the perfusion  
30 direction PD. Thereafter, when the heart undergoes diastolic relaxation the relatively low filling pressures within the left ventricle LV and transmyocardial bloodflow passageway 10 will allow the tissue valve 50 to return to a second or closed position, as illustrated in  
35 Figure 5b. When in such second or closed position, the tissue valve 50 will substantially or completely close off the transmyocardial bloodflow passageway 10, so as to

prevent blood from backflowing or regurgitating in the backflow direction BD, from the lumen of the coronary blood vessel CBV into the transmyocardial bloodflow passageway 10.

5       The tissue valve 50 may be created by any suitable means, including a procedure whereby the tissue penetrating, cutting or boring device used to create the transmyocardial bloodflow passageway is provided with a tapered distal end having a configuration analogous to  
10   that of the inner edge(s) 55 of the wall segment(s) 54 so as to form the desired tissue valve(s) or segment(s) when form the endogenous tissue valve 50, or by another catheter-based device which is equipped to form such tissue valve(s) or segment(s).

15       It will be appreciated that the tissue valve 50 may be formed in various configuration. For example, although the tissue valve 50 shown in Figures 6a and 6b hereof consists of a single flap, various alternative configurations may be utilized wherein multiple tissue  
20   protrusions, multiple tissue flaps, or angularly tapered or funnel shaped tissue flaps are formed to perform the desired valving function. Any and all such configurations of endogenous tissue are intended to be included within the scope of the term "tissue valve" 50  
25   as used herein.

#### VIII.       Elastic Closure for Preventing Backflow Into the Transmyocardial Bloodflow Passageway

30       An alternative to the mechanical valving apparatus 20, 30, 31, 33, 40 or endogenous tissue valve 50 is the elastic closure member 60, shown in Figure 7a and 7b.

      The elastic closure member 6d may comprise one or more sutures formed of stretchable or elastic material such as latex or other elastomeric polymer materials.  
35   Such elastic closure member(s) 60 are preferably passed through adjacent portions of myocardial tissue next to the opening 66 between the transmyocardial bloodflow



passageway 10 and the lumen of the coronary blood vessel CBV (or secondary bloodflow passageway 12).

5 The elastic closure member(s) 60 is the elastically biased to a retracted state whereby the closure member(s) 60 will draw the adjacent portions of myocardium M together so as to close off the opening 66 between the transmyocardial bloodflow passageway 10 and the lumen of the coronary bloodflow CBV, as shown in Figure 7b. Upon systolic contraction of the heart the relatively high pressures created within the left ventricle LV and transmyocardial bloodflow passageway 10 will cause the elastic closure member(s) 60 to stretch or expand, thereby forming opening 66 through which blood may flow from the transmyocardial bloodflow passageway 10 into the lumen of the coronary blood vessel CBV (or secondary bloodflow passageway 12) in the perfusion direction PD, as shown in Figure 7a.

Thereafter, when the heart undergoes diastolic relaxation the relatively low filling pressures within the left ventricle LV and transmyocardial bloodflow passageway 10 will allow the elastic closure member 60 to retract, thereby closing off the opening 66 and preventing blood from backflowing or regurgitating from the lumen of the coronary blood vessel CBV (or secondary bloodflow passageway 12) into the transmyocardial bloodflow passageway 10, in the backflow direction BD, as shown in Figure 7b.

It will be appreciated that the elastic closure member 60 may be installed in any suitable method, such as by way of an appropriate suturing or stapling device which operates to attach the elastic closure member 60 at its desired location. Such installation of the elastic closure member 60 may be accomplished by open surgical technique or by way of catheter-based, transluminal methodology. For example, a catheter having a suturing or stapling device positioned therewithin may be advanced to a position adjacent the opening 66. Thereafter,

negative pressure or other suitable drawings means may be utilized to draw adjacent segments of the myocardial tissue, from either side of the transmyocardial passageway 10, into the catheter. Thereafter, the  
5 desired elastic closure member 60 may be penetrated and threaded through the adjacent sides of the myocardial tissue so as to form the desired elastic closure member 60, as shown.

IX. Protrusive Stents and Stented Grafts for Stenting of  
10 the Transmyocardial Passageway

In accordance with another aspect of the invention shown in Figures 8a-8c, protrusive stents or stented grafts may be positioned within the transmyocardial passageway 10, and may extend into one or more adjacent  
15 coronary vessels including a) an endogenous coronary vein, b) an endogenous coronary artery, c) a man-made passageway in the heart which connects to an endogenous coronary vein, d) a man-made passageway in the heart which connects to an endogenous coronary artery and/or e)  
20 a man-made passageway which extends between an endogenous coronary vein and an endogenous coronary artery. SA described more fully herebelow, the protrusive stent apparatus 90, 90a, 90b of the present invention may incorporate one or more valving apparatus to  
25 intermittently block or direct bloodflow in accordance with various stages of the systolic/diastolic cardiac cycle. Furthermore, such protrusive stent apparatus may optionally be covered or juxtapositioned to a tubular graft or sheath so as to form a discrete tubular  
30 passageway.

Figure 8a shows a non-valved, non-covered protrusive stent apparatus 90 of the present invention positioned partially within a transmyocardial passageway 10, and extending into the coronary vessel CV (e.g., artery, vein  
35 or man-made passageway) to which such transmyocardial passageway 10 extends. As shown, the protrusive stent apparatus 90 is curved or bent at the junction of the

transmyocardial passageway 10 and the coronary vessel CV, and preferably extends into the coronary vessel CV in the desired bloodflow direction.

5 The protrusive stent apparatus 90 may be formed of any suitable material, such as wire mesh or other metal or polymeric material, and may be self-expanding or pressure-expandable.

10 Figure 8b shows a variant of the protrusive stent apparatus 90a positioned partially within a transmyocardial passageway 10, extending through a coronary vein CV, through a secondary passageway 12, and into a coronary artery CA. As shown the protrusive stent apparatus 90a is curved or bent at the junction of the secondary passageway 12 and the coronary artery CA and  
15 preferably extends into the coronary artery CA in the desired bloodflow direction.

Figure 8c shows alternative variations of the protrusive stent apparatus 90b wherein an optional tubular covering 92 is formed on the protrusive stent  
20 90b. Such optional covering 92 may be any suitable tubular covering such as woven polyester or expanded, sintered polytetrafluoroethylene (PTFE). Additionally, or alternatively, one or more valves such as hinged occluder members or pliable elastomeric leaflets may be  
25 located within the protrusive stent apparatus 90b with or without covering 92, at locations  $L_1$  and/or  $L_2$  and/or  $L_3$  to facilitate control and valving of bloodflow through the transmyocardial passageway 10, coronary vein CV, secondary passageway 12 and/or coronary artery CA. It  
30 will be appreciated that embodiments of the protrusive valving apparatus 90b which incorporates such valves at locations  $L_1$  and/or  $L_2$  and/or  $L_3$  may be provided with appropriate openings or apertures in any covering 92 formed thereon to facilitate the desired inflow or  
35 outflow of blood at specific locations thereon.

These protrusive stent apparatus 90, 90a, 90b with or without the optional covering 92 and/or without the

optional valves at locations  $L_1$  and/or  $L_2$  and/or  $L_3$  offer advantages over previously known intramyocardial stents in that they do not require precise cutting to length or precise positioning within the myocardial passageway 10.

5 Indeed, the protrusive stent apparatus 90, 90a, 90b of the present invention are intended to protrude into a coronary blood vessel CBV (e.g., artery, vein and/or man-made passageway) and the length of the portion of the stent apparatus 90, 90a, 90b which extends into such  
10 coronary blood vessel CBV is typically not critical. In this regard, there will exist no need for custom-fitting or precise pre-cutting of the stent apparatus 90, 90a, 90b prior to implantation within the patient.

In embodiments where the stent apparatus 90, 90a, 90b is covered by a partial or complete tubular covering, such covering may be formed of any suitable material including but not necessarily limited to polyester, woven polyester, polytetrafluoroethylene, expanded polytetrafluoroethylene, polyurethane; silicone,  
20 polycarbonate, autologous tissue and, xenograft tissue.

X. Intravascular Valving Apparatus and Method for Intermittent Coronary Venous Occlusion for Enhanced Coronary Perfusion or Regulation of Coronary Venous Pressure  
25

Figures 9-9b are illustrative of a method of the present invention wherein a valving device 110 is positioned within the coronary sinus, great cardiac vein or other coronary vein to control coronary venous  
30 pressure in a manner which results in increased dwell time of arterial blood within a myocardial capillary bed and/or dilation of the capillary bed and/or other improvement of perfusion of an ischemic region of the myocardium M.

35 The theory underlying the mechanism of total or partial venous occlusion, and various embodiments of valves useable to

accomplish such full or partial venous occlusion, are further explained and shown in Figs. 12a-19b.

Figures 12a-12b provide a schematic diagram of the path of blood flow during normal, unrestricted flow (12a), and  
5 valved or blocked flow (12b). In the case of restricted or blocked venous flow, the outflow from the capillary bed is restricted thereby increasing the dwell time of the blood in the capillary bed, and allowing for the ischemic area to be in contact with oxygenated blood for an increased interval,  
10 providing the proposed therapeutic effect.

Several devices can be employed to achieve partial, total or intermittent venous occlusion. The range of therapeutic benefits will depend on the 1) placement of the devices in relation to the ischemic tissue, 2) the rate at which the  
15 heart's second venous system, the Thebesian system, compensates for the blockage and takes over the function of the venous flow through its capillary network, 3) the device used to create the occlusion, namely, the rate of blockage, and whether or not the blockage is valved, and 4) the extent  
20 of the collateralization that may already exist in the circulation. In the event the Thebesian system diverts venous flow and compensates for any flow taken off-line by the placement of a venous block, it may be necessary to valve the blocking device to provide a two-phase effect. In the first  
25 phase, Phase I, the valve is in a closed position, restricting the outflow from the capillary bed and providing the desired benefit. In the second phase, Phase II, the valve opens, releasing the flow into the venous system at an interval such that the Thebesian system does not begin compensating for the  
30 venous blockage and diminishing the therapeutic effect. In this embodiment the degree to which the flow is restricted is a function of both the magnitude of the restriction and its duration. A description of several embodiments follows that address the variations necessary to achieve desired  
35 therapeutic benefits in a given clinical application.

1. Total Occlusion of the Vein. In patients with diffuse cardiovascular disease, therapeutic value may be achieved by

totally blocking the venous system, e.g. continuously blocking blood flow through the vein.

5 a) *Non-valved* - As shown in Figures 13a-13e, total or partial occlusion can be achieved by implantation of a particular embodiment of the valaving device 110, such an embodiment comprising a non-valved, cylindrical blocker 115. In its preferred construction, this blocker 115 comprises a cylindrical frame structure 118 which is fully or partially encased or covered by a tubular polymer 116 or fabric 117 covering or combination thereof. In a preferred embodiment, 10 a sinusoidal wire frame structure 115 is covered with a silicone film 116. In addition to providing an occlusive surface 116(o), this covering 116 aids in shielding the thin walled vein from any trauma caused by the metal struts of the wire frame structure. It is appreciated that the frame 15 structure of the blocker device 115 may be formed of various materials, including stainless steel, NiTi, platinum, titanium and the like. The structure of said frame can be wound wire, a slotted tube, expanded to a larger configuration, or coiled 20 structure. Preferably, the frame structure will be formed of a material such as NiTi that will exert a constant force on the vessel wall, compensating for any enlargement of the vein due to the changes in pressure. In addition, it is appreciated that the blocker device may be fashioned in the form of a wedge-like geometry (not shown) to further ensure 25 secure placement within the vessel.

In some cases, a cap of material is secured to the distal end of the blocking device, to aid in embolization, securement of the device upon placement in a vessel, and ultimately 30 endothelialization (tissue ingrowth). Said cap, 117, can be formed of various materials including polyester fabric (e.g. Dacron™), PTFE, a high-porosity silicone or polyurethane. (see, PCT International Patent Application No. PCT/US97/01463 for further details, the contents of such application being 35 expressly incorporated herein by reference.

b) *Single Pressure Valve* -As shown, the valving apparatus 110 of this invention may be positioned within

a coronary vein, CV (or within the coronary sinus). The valving apparatus 110 may comprise a cylindrical framework or stent 112 having one or more occluder flaps 114 mounted axially therewithin. The occluder flaps 114 have proximal ends PE and distal ends, DE. The proximal ends PE of the occluder flaps 114 define an inflow opening, and the flaps 114 are alternately moveable between a closed configuration wherein the flaps 114 are in abutment with one another so as to block or prevent blood from flowing in the outflow direction OD, and an open configuration wherein the flaps 114 are sufficiently separated from one another to permit blood to flow through the valving apparatus in the outflow direction OD.

In an alternative embodiment, valved structures can be employed that open and allow flow at a certain pressure (P), and close when the pressure goes below P. Certain valves known in the art such as a duckbill valve, slit valve, poppet valve, umbrella valve or like structures can be employed in this manner within an implantable structure for placement into the vein.

c) *Delayed Action Valve* - In contrast to the single pressure valve, embodiments that provide for delayed valving may also be employed, enabling the blockage to be maintained for an extended period of time based on a fixed time delay or a lower closure pressure than that pressure required to open the valve. The length of delay or trigger for release of flow may be timed to the cardiac cycle to maximize the oxygenation phase, or Phase I, and minimize the effect of alternative venous return (such as the Thebesian veins). Examples of such delayed action valves 119, 122, 125, 123 are shown in Figures 14a-18b.

i) *Time Delay Mechanism*. In Figures 14a-14c and 14a'-14b', there are shown alternative embodiment of valves 119, 119' providing for a pressure activated, time-delayed full (119) or partial (119') venous occlusion. A tubular structure is provided with an outer lumen and an inner lumen, said inner lumen

forming a flowable valve flap, 119, 119' containing a viscous substance, such as silicone gel filled balloon (shown), biased to a closed position CP as shown in Fig. 12a. As depicted in Figs. 14b-c, one embodiment of the valve 119 is initially fully closed and, upon being contacted by increasing inflow pressure, move to an open configuration and remain open for a period of time sufficient for the viscous substance to settle back to its original biased position. The time delay is a function of the viscosity of the flowable substance, which can be varied depending on the desired length of delay. A similar embodiment of the valve 119' shown in Figures 14a' and 14b' operates in the same manner as the above-described valve 119, but does not completely occlude venous return even when in its fully closed state (Fig. 14a').

ii) **Magnetic Valve.** In a further embodiment as shown in Fig. 15 the valving apparatus comprises a tubular structure or valve body 122, having an inflow direction (IF) and an outflow direction (OF), and further having a valving member comprised of a substantially cylindrical ferrous element 123, detachably coupled with a fixed magnetic surface 124, located at the inflow IF end of the valve body. In a first or closed position, the valving member 123 and the magnetic surface 124 are coupled thereby blocking flow through the valve body. The magnetic force of the coupling between the valving member 123 and the magnetic surface 124 dictates the opening pressure of the valve. When the pressure exerted by blood flow in the inflow direction is sufficient to overcome the magnetic force of the coupling between the valving member 123 and the magnetic surface 124 (P1 or opening pressure), the valving member 123 is dislodged, allowing flow to travel through the valve body. The time delay function of this embodiment occurs during the interval when the



pressure in the inflow direction falls below P1 and the valving member 123 is drawn back into contact with the magnetic surface 124 of the valve body by the magnetic force existing between them.

5       iii) **Oxygen sensor valve.** With reference to Figures 16 and 16a, the time delay mechanism may also be a function of the level of oxygenation sensed by the valving apparatus. This embodiment of the valving apparatus is triggered to an open or closed position  
10       based upon the percent oxygenation it senses at its inlet port. In a further embodiment as shown in Figures 16 and 16a, this valving apparatus has an inlet port IP and an outlet port OP and a flowthrough lumen provided therebetween. A septum  
15       125 disposed within the flowthrough lumen, thereby separating the valving apparatus into two chambers, and inflow chamber IFC and an outflow chamber OFC. Said septum 125 being comprised of a valved structure 126 having an oxygen sensor 127 mounted thereon.  
20       Said oxygen sensor 127 triggers the valve to be in an open or closed position, depending on the percent oxygenation in the inflowing blood. As blood flow travels into the inflow chamber IFC, it contacts the oxygen sensor 127. Said sensor maintains the valved  
25       structure in a closed position until a preset desired oxygen content is reached within the blood in the inflow chamber IFC. Upon sensing the desired, pre-set oxygenation level, the valved structure opens and releases flow into the outflow chamber OFC and the  
30       venous system.

d) **Pressure Delay Mechanism.** It may be desirable to have valve structures that open and close along a certain hysteresis curve as shown graphically in Fig. 17. In a first embodiment shown in Fig. 16, a device having a  
35       tubular structure with an inflow direction (IF) and outflow direction (OF), having a piston mechanism 128 that is set to open at a pressure (P1), and remain open

until the pressure falls below  $P_2$ , where  $P_2$  is less than  $P_1$ . The piston 128 is biased towards a closed position with a spring-like member 129, which is secured to strut member on the outflow end of the device. In the closed position, the piston member abuts a ledge 130, provided by the inner contour of the tubular structure. Further defined by the inner contour of the tubular structure is an inlet port (IP) and an outlet port (OP) defining a flow path therethrough. In the closed position, a fluid seal is created between the piston and the ledge, thereby blocking flow between the inlet port IP and the outlet port OP, and defining certain chambers within the tubular structure; an inflow chamber (IFC), and outflow chamber (OFC), a pressure chamber (PC). In operation, the force on the piston in the closed position is equal to the pressure of the fluid at the inlet port IP multiplied by the surface area 1 ( $SA_1$ ). When the force exceeds a certain threshold  $F_t$ , the correlating pressure  $P_1$  will cause the piston to travel toward the OP, thereby compressing the spring mechanism 129, and allowing flow to travel from IFC to OFC. In the open position, fluid communication is established between the inflow chamber IFC and the pressure chamber PC, thus increasing the force on the piston by an amount equal to the pressure at the inlet port IP multiplied by surface area 2 ( $SA_2$ ). The increased surface area allows a lower pressure  $P_2$  to generate sufficient force above that of the value of  $F_t$ , thereby maintaining the valve in the open position. When pressure decreases below  $P_2$ , the valve will close and the hysteresis cycle can be repeated (i.e. the valve will not re-open until a pressure  $P_1$  is achieved.) In clinical application, this results in an intermittent occlusion of venous flow which may prevent the activation of alternative venous conduits such as the Thebesian veins. The desired crack open pressure and hold open pressure is a function of the spring force of spring member 129, and the values of

SA1 and SA2 and can be varied depending on the activity intervals desired.

2. Partial Occlusion of the Vein. In a similar method to placing a total blocking system, a partial blocker may also be placed in an alternative embodiment, wherein flow through the valve body is never fully blocked, but is restricted to the degree necessary to achieve a therapeutic benefit.

5 a) **Non-valved** - In an embodiment similar to that described in Fig. 11, an opening, 120 can be formed in the distal tip of the blocking device, sufficient to provide for a certain amount of flow therethrough, while still providing a restriction sufficient to achieve a therapeutic effect.

10 b) **Single Pressure Valve** - Similarly, as shown in Fig. 14a-c and 14a'-b', for example, in the case of the flowable valve, it is appreciated that the flaps of said valve may be positioned such that in the closed or fully biased position, they do not contact each other, thereby affecting a narrowing of flow through the valve body. In operation, the action of the valve in response to the inflow pressure of the blood flow (e.g. viscous biasing) varies the diameter of the narrowing, but does not act to totally occlude the valve lumen.

15 c) **Delayed Action Valve** - It may be desirable to provide the combined effect of a partial blockage (i.e. reduced by continuous flow) and a hysteresis, or delayed action valve. Toward this end, it is appreciated that the delayed action valve embodiments described above may additionally provide a flow through lumen positioned within the tubular valving apparatus. For example, in the partial-occlusion embodiment of Figures 19a-19b, the pressure delay valving apparatus 123' includes a flow through lumen 120 which allows continuous flow through the valve body even when the occluder 128 is in its closed position (Figure 19a), while in the full-occlusion embodiment shown in Figures 18a-18b, no flow-

through passageway is provided and, when the occluder 128 is in its closed position (Figure 18a) the flow of blood through the vein will be totally blocked.

3. Method of Implantation - Femoral or jugular vascular  
5 access is gained to the venous system via standard sheath and dilator placement in the femoral or jugular vein. A coronary sinus access catheter is placed to cannulate the coronary sinus to assist in the placement of guidewires into the GCV and AIV over which subsequent interventional devices will be  
10 placed, including the blocking devices described hereabove. A coronary sinus guide catheter (not shown), with introducer dilator is advanced over the GCV/AIV wire until the tip of the guide is deep seated past the "mouth" of or entrance to the coronary sinus. The introducer dilator is then removed. A  
15 blocker delivery catheter, Not shown is advanced over the GCV/AIV guidewire under flouroscopy to a position in the vein approximate the ischemic segment. The GCV/AIV guidewire is then removed, and a blocker is inserted into the proximal end of the delivery catheter. A push rod, (not shown) is then  
20 inserted into the blocker delivery catheter, and the blocker device is pushed until it exits the delivery catheter and expands into position in the vein.

The positioning of the blocker varies depending on the location of the ischemic region. Preferably, a blocker is  
25 placed in the vein to occlude the specific venous return flow from the region. It is appreciated that it may be necessary to block multiple small veins, or the larger main venous conduits fed by the smaller veins.

A transmyocardial passageway 10 of the present invention  
30 may optionally, but not necessarily, be formed between a chamber of the heart such as the left ventricle IV and the coronary vein CV such that oxygenated blood may enter the lumen of the coronary vein CV to enhance the retroperfusion of the myocardium M.

35 The flaps 114 of the valving apparatus 110 are constructed so as to be biased to their closed configuration, but so as to separate and move to their open configuration when the pressure of blood exerted against the flaps 114 in

the outflow direction OD exceeds a predetermined maximum amount. This causes the pressure of blood within the coronary vein to exceed its normal pressure during a portion of the cardiac cycle. This is illustrated in Figure 9b wherein the normal pressure of blood within the coronary vein CV is illustrated by the dotted line, and wherein the modified pressure of blood within the coronary vein having the valving apparatus 110 of the present invention positioned therein is illustrated by the solid line. As shown, the valving apparatus 110 of the present invention serves to cause the pressure of blood within the coronary vein CV to raise to a substantially higher level (e.g., 40/hg) before the occluder flaps 114 of the valving apparatus 110 move to their open configuration, thereby allowing the pressure of blood within the coronary vein CV to once again fall.

It will be appreciated that the valving apparatus 110 of the present invention may optionally incorporate one or more of the following additional features:

- The valving apparatus may be puncturable or traversable so as to permit a catheter to be passed through the valving apparatus in the event that such catheter passage becomes necessary at a later time;
- The valving apparatus may be removable such that it may be rescued and removed from the body in the event it is no longer necessary, or if removal becomes desirable for some other reason;
- The valving apparatus may be provided with projections, hooks, material for tissue in growth, or other suitable anchoring apparatus to assist in holding the valving apparatus in its desired position within the venus lumen; and
- The valving apparatus may be formed of radiologically imaggable material, or may be provided with one or more radio dense or radio opaque markers to facilitate visualization of the valving apparatus by x-ray or fluoroscopy.

It is to be further appreciated that any of the transmyocardial passageways between a chamber of the heart and

a coronary blood vessel CBV may be formed by any suitable means. In many instances, it will be desirable to pass a passageway-forming catheter 100 into one of the coronary blood vessels CBV and subsequently orienting the catheter such that  
5 the tissue-penetrating element of the catheter will pass from the coronary blood vessel CBV within which it is located into a chamber of the heart, such as the left ventricle. (see Fig. 11a) Alternatively, as shown in Figure 10, a passageway-forming catheter 100a may be advanced into a chamber of the  
10 heart, such as the left ventricle LV, and will be oriented/positioned such that the tissue-penetrating element 102a of the catheter 100a is directed to the desired coronary blood vessel CBV. Thereafter, the tissue-penetrating element 102a is passed from  
15 the passageway-forming catheter 100a, through the wall of the myocardium M and into the desired coronary blood vessel CBV. A guidewire 104a may optionally be advanced through an optional lumen in the tissue-penetrating element 102a and into the coronary blood vessel CBV such that the tissue-penetrating  
20 element 102a may subsequently be retracted into the catheter 100a leaving the guidewire 104a extended through the transmyocardial passageway 10 and into the coronary blood vessel CBV. Thereafter, one or more passageway-modifying apparatus may be advanced over the guidewire 104a to modify or  
25 complete the formation of the desired transmyocardial passageway 10.

It will be appreciated that specific passageway-forming catheter devices 100, 100a, specific tissue-penetrating elements 102, 102a, and ancillary apparatus for modifying  
30 (e.g., sleeving, cauterizing, enlarging, stenting, valving, etc.) the transmyocardial passageway 10 have been fully described and claimed in earlier-filed applications of which this is a continuation-in-part.

The foregoing invention has been described hereabove with  
35 reference to certain presently preferred embodiments and examples only. No effort has been made to exhaustively describe all possible embodiments and examples in which the invention may be practiced. Indeed, various additions,

deletions, modifications and alterations may be made to the above-described embodiments and examples without departing from the intended spirit and scope of the invention. Accordingly, it is intended that all such additions, deletions  
5 and modifications and alterations be included within the scope of the following claims.

2007-07-06

WHAT IS CLAIMED IS:

1. A method for transmyocardial coronary revascularization, said method comprising the step of:

5 a) creating a transmyocardial bloodflow passageway between a chamber of the heart and a coronary vein.

2. The method of Claim 1 wherein said passageway is formed such that blood will flow from the chamber of the heart, through the transmyocardial bloodflow passageway, and through the lumen of the coronary vein, in a retrograde  
10 direction, so as to perfuse said region of the myocardium.

3. The method of Claim 1 wherein said coronary vein is situated next to a coronary artery, and wherein said method further comprises the step of:

15 b) forming a fistulous connection between said coronary vein and said adjacent coronary artery, at a location which is downstream of said transmyocardial bloodflow passageway, such that blood may flow from the chamber of the heart, through said transmyocardial bloodflow passageway, through said vein, through said  
20 fistulous connection, and into the adjacent coronary artery so as to provide enhanced bloodflow through said coronary artery.

4. The method of Claim 3 wherein said fistulous connection is a secondary bloodflow passageway which extends  
25 from said coronary vein to said coronary artery.

5. The method of Claim 1, further comprising the additional step of:

30 b) blocking the lumen of the coronary vein at a location which is upstream of said transmyocardial bloodflow passageway.

6. The method of Claim 3 wherein said method further comprises the steps of:

blocking the lumen of the coronary vein at a location downstream of said fistulous connection.

35 7. The method of Claim 1 further comprising the step of:

b) placing an intraluminal valving apparatus within the lumen of the coronary vein, said intraluminal



bloodflow passageway, said tissue valve will move to its closed position.

16. The method of Claim 1 further comprising the step of:

5 connecting an elastic closure member to cardiac tissue on either side of said transmyocardial bloodflow passageway, said elastic closure member being alternately transitionable between:

- 10 i) a stretched configuration whereby said transmyocardial bloodflow passageway is opened to permit blood to flow from said transmyocardial bloodflow passageway into said coronary vein; and
- 15 ii) a retracted configuration whereby said transmyocardial bloodflow passageway is substantially blocked so as to prevent blood from backflowing from said coronary vein into said transmyocardial bloodflow passageway.

17. The method of Claim 16 wherein said elastic closure member comprises a suture which is formed of  
20 elastic material, said suture being threaded through said myocardial tissue on opposite sides of said transmyocardial bloodflow passageway.

18. The method of Claim 1 further comprising the step of:

25 b) placing an intracardiac valving apparatus within the chamber of the heart, adjacent one end of said transmyocardial bloodflow passageway, said intracardiac valving apparatus being alternately deployable in:

- 30 i) an open position whereby bloodflow is permitted to pass through the transmyocardial bloodflow passageway in a first direction; and,
- 35 ii) a closed position whereby blood is prevented from backflowing through the transmyocardial bloodflow passageway, in a second

12. The method of Claim 1 further comprising the step of:

c) forming an endogenous tissue valve which is alternately moveable between:

5 i) an open position whereby bloodflow is permitted to pass from said transmyocardial bloodflow passageway and through the lumen of said coronary vein, in a perfusion direction; and,

10 ii) a closed position whereby said tissue valve will prevent blood from flowing from the coronary vein into said transmyocardial bloodflow passageway, in a backflow direction.

13. The method of Claim 12 wherein said tissue valve is formed at the junction of the transmyocardial bloodflow passageway and the coronary vein.

14. The method of Claim 13 wherein the tissue valve comprises at least one segment of the coronary vein in combination with at least one underlying segment of myocardial tissue.

15 15. The method of Claim 14 wherein at least one segment of coronary vein and the at least one segment of underlying tapered segment of myocardial tissue which form said tissue valve are sized and configured such that, when systolic blood pressure is created within said transmyocardial bloodflow passageway, said tissue valve will move to its open position, and thereafter when diastolic blood pressure is present in said transmyocardial bloodflow passageway, said tissue valve will move to its closed position.

16. The method of Claim 1 further comprising the step of:

connecting an elastic closure member to cardiac tissue on either side of said transmyocardial bloodflow passageway, said elastic closure member being alternately transitionable between:

35 i) a stretched configuration whereby said transmyocardial bloodflow passageway is opened to permit blood to flow from said transmyocardial bloodflow passageway into said coronary vein; and

ii) a retracted configuration whereby said transmyocardial bloodflow passageway is substantially blocked so as to prevent blood from backflowing from said coronary vein into said transmyocardial bloodflow passageway.

17. The method of Claim 16 wherein said elastic closure member comprises a suture which is formed of elastic material, said suture being threaded through said myocardial tissue on opposite sides of said transmyocardial bloodflow passageway.

18. The method of Claim 1 further comprising the step of:

b) placing an intracardiac valving apparatus within the chamber of the heart, adjacent one end of said transmyocardial bloodflow passageway, said intracardiac valving apparatus being alternately deployable in:

i) an open position whereby bloodflow is permitted to pass through the transmyocardial bloodflow passageway in a first direction; and,

ii) a closed position whereby blood is prevented from backflowing through the transmyocardial bloodflow passageway, in a second direction, said second direction being opposite said first direction.

19. The method of Claim 18 wherein said transmyocardial bloodflow passageway is intended to provide a flow of blood from the chamber of the heart to the coronary vein, and wherein said first direction is the direction extending from the chamber of the heart to the coronary vein, and said second direction is the direction extending from the coronary vein to the chamber of the heart.

20. The method of Claim 18 wherein said transmyocardial bloodflow passageway is intended to drain blood from the coronary vein into the chamber of the heart, and wherein said first direction is the direction extending from the coronary vein to the chamber of the heart, and said second direction is the direction extending from the chamber of the heart to the coronary vein.

21. The method of Claim 18 wherein the intracardiac valving apparatus provided in step b is attached to the wall of the chamber of the heart, and is positioned over the opening formed in the chamber of the heart by said transmyocardial bloodflow passageway.

22. The method of Claim 21 wherein said intracardiac valving apparatus is sutured to the wall of the chamber of the heart.

23. The method of Claim 21 wherein said intracardiac valving apparatus is adhered to the wall of the chamber of the heart.

24. The method of Claim 1 further comprising the step of:

b) placing a protrusive stent within said transmyocardial passageway, such that said protrusive stent extends into said coronary vein.

25. The method of Claim 24 wherein said protrusive stent is uncovered.

26. The method of Claim 24 wherein said protrusive stent is at least partially covered.

27. The method of Claim 24 wherein said protrusive stent incorporates at least one valve to intermittently block blood flow, in at least one direction, through said transmyocardial passageway.

28. The method of Claim 27 wherein said valve is operative to permit blood to flow from said chamber of the heart through said transmyocardial passageway, and into said coronary vein, but will prevent blood from backflowing from said coronary vein into said transmyocardial passageway.

29. A method for transmyocardial direct coronary revascularization, said method comprising the steps of:

a) forming a transmyocardial bloodflow passageway from a chamber of the heart to a coronary blood vessel;

b) permitting blood to flow from the chamber of the heart, through said transmyocardial bloodflow passageway; and

30. The method of Claim 29 wherein said blood vessel is  
5 selected from the group consisting of:

- 10

15

20

- 25

30

- 35

d) blocking the lumen of the coronary vein downstream of said fistulous connection.

35. The method of Claim 29 further comprising the step of:

d) placing an intraluminal valving apparatus within the lumen of the coronary blood vessel, said intraluminal valving apparatus comprising at least one occluder member which is alternately deployable in:

i) an open position whereby bloodflow is permitted to pass from said transmyocardial bloodflow passageway and through the lumen of the coronary vein in a perfusion direction; and,

ii) a closed position whereby blood is prevented from flowing from the coronary vein into said transmyocardial bloodflow passageway, in a backflow direction.

36. The method of Claim 35 wherein the intravascular valving apparatus of step C is positioned downstream of the transmyocardial bloodflow passageway, and wherein said method further comprises the step of:

e) blocking the lumen of the coronary vein upstream of the transmyocardial bloodflow passageway.

37. The method of Claim 29 further comprising the step of:

c) forming an endogenous tissue valve which is alternately moveable between:

i) an open position whereby bloodflow is permitted to pass from said transmyocardial bloodflow passageway and through the lumen of said coronary vessel, in a first direction; and,

ii) a closed position whereby said tissue valve will prevent blood from flowing from the coronary vein into said transmyocardial bloodflow passageway, in a second direction opposite said first direction.

38. The method of Claim 37 wherein said tissue valve is formed at the junction of the transmyocardial bloodflow passageway and the coronary blood vessel.

39. The method of Claim 38 wherein the tissue valve comprises at least one segment of the coronary blood vessel in

combination with at least one underlying segment of myocardial tissue.

40. The method of Claim 37 wherein at least one segment of coronary blood vessel and at least one underlying tapered  
5 segment of myocardial tissue which form said valving tissue valve are sized and configured such that, when systolic blood pressure is created within said transmyocardial bloodflow passageway said tissue valve will move to its open position, and thereafter when diastolic blood pressure is present in  
10 said transmyocardial bloodflow passageway, said tissue valve will move to its closed position.

41. The method of Claim 29 further comprising the step of:

connecting an elastic closure member to the  
15 myocardial tissue on either side of said transmyocardial bloodflow passageway, said elastic closure member being alternately transitionable between:

i) a stretched configuration whereby an opening is formed to permit blood to flow from said  
20 transmyocardial bloodflow passageway into said coronary vein; and

ii) a retracted configuration whereby said opening is substantially closed, thereby preventing blood from backflowing from said coronary vein into  
25 said transmyocardial bloodflow passageway.

42. The method of Claim 41 wherein said elastic closure member is a suture which is formed of elastic material and passed through said myocardial tissue on opposite sides of said transmyocardial bloodflow passageway.

30 43. The method of Claim 29 further comprising the step of:

b) placing a protrusive stent within said transmyocardial passageway, such that said protrusive stent extends into said coronary vessel.

35 44. The method of Claim 43 wherein said protrusive stent is uncovered.

45. The method of Claim 43 wherein said protrusive stent is at least partially covered.

46. The method of Claim 43 wherein said protrusive stent incorporates at least one valve to intermittently block blood flow, in at least one direction, through said transmyocardial passageway.

47. The method of Claim 46 wherein said valve is operative to permit blood to flow from said chamber of the heart through said transmyocardial passageway, and into said coronary vessel, but will prevent blood from backflowing from said coronary vein into said transmyocardial passageway.

48. An intraluminal valving apparatus which is operative to prevent blood from a backflowing from a coronary blood vessel into a transmyocardial bloodflow passageway which extends from a chamber of the heart to said coronary blood vessel, said apparatus comprising:

a generally cylindrical body having an axial bore which extends longitudinally therethrough; and,

at least one occluder member positioned within said axial bore, said at least one occluder member being alternately moveable between:

i) an open position whereby systolic blood is permitted to pass from said transmyocardial bloodflow passageway, through the lumen of the coronary blood vessel; and,

ii) a closed position whereby blood is prevented from backflowing from the lumen of the coronary blood vessel into the transmyocardial bloodflow passageway.

49. The valving apparatus of Claim 48 wherein said generally cylindrical body is initially of a radially compact diameter so as to be transluminally advanceable through the vasculature into said blood vessel, and is subsequently expandable to a second radially expanded diameter wherein said cylindrical body will contact and engage the surrounding wall of said blood vessel.

50. The valving apparatus of Claim 49 wherein said cylindrical body is self-expanding.

51. The valving apparatus of Claim 49 wherein said cylindrical body is pressure-expandable.



52. The valving apparatus of Claim 48 further comprising:

5 a side aperture formed in the cylindrical body of said apparatus, said side aperture being alienable with said transmyocardial bloodflow passageway such that blood from said transmyocardial bloodflow passageway may flow through said side aperture and into the axial bore of the valving apparatus.

10 53. The valving apparatus of Claim 52 wherein said at least one occluder member is configured to close off said side aperture when in it's closed position, and further such that a subsequent increase in blood pressure within the transmyocardial bloodflow passageway will move said occluder member to said open position, thereby reopening said side  
15 aperture.

20 54. The valving apparatus of Claim 53 wherein said at least one occluder member is positioned within the axial bore of the apparatus, at a location downstream of said side aperture, such that systolic bloodflow which passes from the transmyocardial bloodflow passageway into the axial bore of the apparatus will force said occluder member to its open position, thereby causing the bloodflow to continue in the downstream direction, and the subsequent creation of diastolic blood pressure is within the transmyocardial bloodflow  
25 passageway will move said occluder member to its closed position thereby preventing blood from backflowing out of said side aperture and into said transmyocardial bloodflow passageway.

30 55. The valving apparatus of Claim 53 further comprising:

a blocking member which closes off the axial bore of the apparatus, upstream of said side aperture.

56. The valving apparatus of Claim 48 further comprising:

35 a secondary occluder member which closes off the axial bore of the apparatus, upstream of said side aperture.

57. The valving apparatus of Claim 48 wherein the apparatus is intended to be positioned within said coronary blood vessel at a location downstream of said junction between said blood vessel and said transmyocardial bloodflow passageway, and wherein:

said at least one occluder member which is configured to permit blood to flow in a perfusion direction through said axial bore, when said at least one occluder member is in it's open position, and to prevent blood from backflowing through said axial bore in a backflow direction, when said occluder member is in its closed position.

58. A system comprising two of the valving apparatus of Claim 48, one of said valving apparatus being positionable within said coronary blood vessel upstream of said transmyocardial bloodflow passageway, and the other of said valving apparatus being positionable within said coronary blood vessel downstream of said transmyocardial bloodflow passageway.

59. An intracardiac valving apparatus which is operative to control bloodflow through a transmyocardial bloodflow passageway extending from a chamber of the heart to a coronary blood vessel, said intracardiac valving apparatus comprising:

a valve body having an opening formed therethrough, said valve body being positionable in contact with the wall of the heart such that the opening of said valve body is in alignment with said transmyocardial bloodflow passageway;

at least one occluder member positioned within the opening of said valve body, said occluder member being alternately moveable between:

i) an open position whereby blood is permitted to pass through said transmyocardial bloodflow passageway in a first direction; and,

ii) a closed position whereby blood is prevented from flowing through said transmyocardial

passageway in at least a second direction opposite said first direction.

60. The intracardiac valving apparatus of Claim 59 wherein said apparatus further comprises:

5 means for holding said intracardiac valving apparatus in substantial fixed position against said wall of the chamber of the heart.

61. The intracardiac valving apparatus of Claim 60 wherein said means for holding comprises hooks.

10 62. The intracardiac valving apparatus of Claim 61 wherein said means for holding comprises sutures.

63. The intracardiac valving apparatus of Claim 61 wherein said means for holding comprises an adhesive.

15 64. The intracardiac valving apparatus of Claim 61 wherein said means for holding comprises a retainer assembly which engages the heart, and which exerts force upon said intracardiac valving apparatus to hold said intracardiac valving apparatus to hold said intracardiac valving apparatus in substantially fixed position.

20 65. The intracardiac valving apparatus of Claim 64 wherein said retainer assembly comprises:

25 a generally annular retainer ring having an aperture formed therein, said generally annular retainer ring positionable within the coronary blood vessel such that the aperture formed therein is in alignment with the transmyocardial passageway; and,

30 at least one elastomeric tether member having a first end connected to said intracardiac valving apparatus and a second end connected to said retainer ring, said elastomeric tether member being of a length and resiliency which is sufficient to exert sufficient inward pressure upon said valving apparatus and said retainer ring to hold said valving apparatus and said retainer ring in substantially fixed positions, with the  
35 aperture of the valving apparatus and the aperture of the retainer ring being in alignment with said transmyocardial passageway.

66. A protrusive stent apparatus for stenting a transmyocardial passageway which extends from a chamber of the heart to a coronary blood vessel, said apparatus comprising:

5           a tubular body which is alternately configureable in:

          i)    a radially collapsed configuration of a first diameter;

          ii) a radially expanded configuration of a second diameter, said second diameter being at  
10       least as large as the diameter of the transmyocardial passageway;

          said protrusive stenting apparatus having a length which is longer than the length of the transmyocardial passageway, such that said apparatus may be positioned  
15       within said transmyocardial passageway from said cardiac chamber to said coronary blood vessel, with a portion of said apparatus protruding into said coronary blood vessel.

67. The protrusive stent apparatus of Claim 66 wherein  
20       the tubular body of said stent apparatus is self-expanding.

68. The protrusive stent apparatus of Claim 66 wherein the tubular body of said stent apparatus is pressure expandable.

69. The protrusive stent apparatus of Claim 66 wherein  
25       the tubular body of said stent apparatus is formed of material selected from the group of materials consisting of:

          metal;

          polymeric material.

70. The apparatus of Claim 66 wherein said apparatus  
30       further comprises:

          a tubular covering formed on said stent.

71. The apparatus of Claim 70 wherein said tubular covering is formed of a material selected from the group of materials consisting of:

35       polyester;

          woven polyester;

          polytetrafluroethylene;

          expanded polytetraflouroethylene;

polyurethane;  
silicone;  
polycarbonate;  
autologous tissue; and,  
5 xenograft tissue.

72. The apparatus of Claim 66 wherein said apparatus further comprises:

at least one valve positioned within said tubular body to control bloodflow therethrough.

10 73. A method for transmyocardial coronary revascularization of a coronary artery having an occlusion formed therein, said method comprising the steps of:

a) providing a passageway-forming catheter comprising an elongate pliable catheter body having at  
15 at least one tissue-penetrating element which is passable from the catheter body to form an interstitial passageway through tissue;

b) inserting the passageway-forming catheter into the venous vasculature and advancing the catheter  
20 until a distal portion of the catheter is located within a coronary vein adjacent the coronary artery wherein the obstruction is present;

c) orienting the passageway-forming catheter such that the tissue-penetrating element is directed  
25 toward the coronary artery at a site downstream of the obstruction;

d) passing the tissue-penetrating element from the passageway-forming catheter, through the wall of the  
30 coronary vein wherein the catheter is positioned, through any tissue located between the coronary vein and the coronary artery, through the wall of the coronary artery and into the coronary artery, downstream of the obstruction, thereby forming an arterio-venous passageway between said coronary artery and said  
35 coronary vein;

e) advancing the passageway-forming catheter through the arterio-venous passageway and into the coronary artery, downstream of the obstruction;

f) orienting the passageway-forming catheter such that the tissue-penetrating element is directed toward a chamber of the heart;

5 g) passing the tissue-penetrating element from the passageway-forming catheter, through the wall of the coronary artery, through the myocardium and into a chamber of the heart, thereby forming a transmyocardial passageway through which blood may flow from the chamber of the heart and into the coronary artery, downstream of  
10 the obstruction;

h) removing the passageway-forming catheter from the body;

i) closing the arterio-venous passageway which had been formed in step d.

15 74. The method of Claim 73 wherein step i comprises placing an occlusion apparatus within said arterio-venous passageway.

75. The method of Claim 73 wherein step i comprises applying energy to the tissue surrounding said arterio-venous  
20 passageway to close said arterio-venous passageway.

76. The method of Claim 75 wherein the energy utilized to close said arterio-venous passageway is selected from the group of energy types consisting of:

electrocautery, heat, radiofrequency, and light.

25 77. A method for treating myocardial ischemia, said method comprising the steps of:

a) providing a intravascular valving apparatus, said apparatus comprising a frame which is engageable with a surrounding vascular wall and at least one  
30 occluder mounted in said frame, said occluder being alternately moveable between a closed position wherein said occluder will block the flow of blood in an outflow direction through said coronary vein, in an open position wherein said occluder will permit blood to flow  
35 in said outflow direction through said coronary vein, said occluder being biased to its closed position but being moveable to its open position when the pressure of

blood within the coronary vein exceeds a predetermined maximum pressure;

b) implanting the intervascular valving apparatus at a first location within the coronary venous vasculature such that the occluder member of said valving apparatus will prevent the flow of blood in an outflow direction from at least one coronary vein until such time as the pressure of blood within that coronary vein exceeds said predetermined maximum pressure.

78. The method of Claim 77 wherein said method further comprises:

forming a transmyocardial passageway from said coronary vein to a chamber of the heart such that blood may flow from the chamber of the heart, through the transmyocardial passageway, and into the coronary vein.

79. The method of Claim 78 wherein said myocardial passageway is formed between the left ventricle of the heart and said coronary vein such that oxygenated blood from the left ventricle will flow through the transmyocardial passageway and into the coronary vein.

80. The method of Claim 77 wherein the intravascular valving apparatus is implanted within the coronary sinus.

81. The method of Claim 77 wherein the intravascular valving apparatus is implanted within the great cardiac vein.

82. A method for performing an intraluminal medical procedure within the lumen of an obstructed coronary artery, at a site downstream of the obstruction, said method comprising the steps of:

a) providing a passageway-forming catheter comprising an elongate pliable catheter body having at least one tissue-penetrating element which is passable from the catheter body to form an interstitial passageway through tissue;

b) inserting the passageway-forming catheter into the venous vasculature and advancing the catheter until a distal portion of the catheter is located within a coronary vein adjacent the coronary artery wherein the obstruction is present;

5                   d)     passing the tissue-penetrating element from  
the passageway-forming catheter, through the wall of the  
coronary vein wherein the catheter is positioned,  
through any tissue located between the coronary vein and  
the coronary artery, through the wall of the coronary  
0     artery and into the coronary artery, downstream of the  
obstruction, thereby forming an arterio-venous  
passageway between said coronary artery and said  
coronary vein;

15

20

83. The method of Claim 82 wherein said intraluminal procedure is selected from the group of intraluminal procedures consisting of:

25

30           a thrombolytic procedure wherein a thrombus within  
          the coronary artery is lysed;

30

35



9400 10

5

Figure 1. The structure of the proposed model. The model is composed of three parts: the input layer, the hidden layer, and the output layer. The input layer consists of 10 nodes, the hidden layer consists of 10 nodes, and the output layer consists of 10 nodes. The model is trained using a genetic algorithm (GA) to optimize the weights and biases of the network. The GA is applied to the hidden layer weights and biases, while the input and output layer weights and biases are fixed. The model is evaluated using a set of test data, and the performance is measured using the mean squared error (MSE) and the coefficient of determination (R-squared).

Abstract



Methods and apparatus for direct coronary  
revascularization wherein a transmyocardial passageway is  
formed between a chamber of the heart and a coronary blood  
5 vessel to permit blood to flow therebetween. In some  
embodiments, the transmyocardial passageway is formed between  
a chamber of the heart and a coronary vein. The invention  
includes unstented transmyocardial passageways, as well as  
transmyocardial passageways wherein protrusive stent devices  
10 extend from the transmyocardial passageway into an adjacent  
coronary vessel or chamber of the heart. The apparatus of the  
present invention include protrusive stent devices for  
stenting of transmyocardial passageways, intraluminal valving  
devices for valving of transmyocardial passageways,  
15 intracardiac valving devices for valving of transmyocardial  
passageways, endogenous tissue valves for valving of  
transmyocardial passageways, and ancillary apparatus for use  
in conjunction therewith.








20

25

30

35








Fig. 3a




Fig 3b




Fig. 5a









Fig. 5






Fig. 8a




Fig. 8b




Fig. 8c

000001-000000




Fig. 9




Fig. 9a










Fig. 9b



Fig. 9c

CORONARY VENOUS  
PRESSURE  
(mm/hg)FLOW  
(100 ml/min.)








Fig. 13b




Fig. 13c




Fig. 13d




Fig. 13E




Fig. 14a




Fig 146




Fig 14c




Fig. 14a'




Fig. 14b'






Fig. 15



Valve Position




Fig. 1.7




Fig. 18a




Fig. 18b






Fig. 19a




Fig. 19b

006077 22607 260

**DECLARATION OF INVENTORSHIP and  
LIMITED POWER OF ATTORNEY**

As a below named inventor, I believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the invention entitled "Methods and Apparatus for Transmyocardial Direct Coronary Revascularization," which is described and claimed in Application No. 09/059,531 filed 04/13/98 and for which a patent is sought. My residence, post office address and citizenship are as stated below next to my name.

I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to herein.

I acknowledge my duty under Title 37, Code of Federal Regulations § 1.56(a) to disclose information which is material to the patentability of the invention I am claiming.

☒ I hereby claim the benefit under Title 35 United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35 United States Code § 112, I acknowledge the duty to disclose material information as defined in Title 37 Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

United States Patent Application 08/730,496 filed October 11, 1996

United States Patent Application 08/837,295 filed April 11, 1997

As a named inventor and until I assign my rights to the invention, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith on my behalf: STEVEN C. SEREBOFF, Reg. No. 37,035, ROBERT D. BUYAN, Reg. No. 32,460, and RIVA W. BICKEL, Reg. No. 34,777. Send correspondence and direct telephone calls to: Mary J. Campbell, SEREBOFF & BUYAN, 2600 Michelson Drive, Suite 770, Irvine CA 92612; telephone 949/261-2252 x21, facsimile 949/261-2988, email: mcampbell@iplawexperts.com.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application and any patent issuing thereon.

Joshua (NMI) Makower, of Los Altos, California, a citizen of U.S.A. Post office address: 450 Tyndall Street, Los Altos, CA 94025

Signature: [Signature] Date: 5/28/98

J. Christopher Flaherty of Los Altos, California, a citizen of U.S.A. Post office address: ~~766 La Prenda Road~~, Los Altos, CA 94024

Signature: [Signature] Date: 5/29/98

11 PINE LANE  
CT 5/29/98

Timothy R. Machold of Moss Beach, California, a citizen of U.S.A. Post office address: 56 Bernal Avenue, Moss Beach, CA 94024

Signature: [Signature] Date: 6/16/98

Jason Brian Whitt, of San Francisco, California, a citizen of U.S.A. Post office address: 2554 Franklin Street, San Francisco, CA 94133

Signature: [Signature] Date: 5/29/98

Margaret W. Tumas, of Orinda, California, a citizen of U.S.A. Post office address: 3 Rae Court, Orinda, CA 94563

Signature: [Signature] Date: 5/29/98

Theodore C. Lamson of Pleasanton, California, a citizen of U.S.A.. Post office address: 2172 Camino Brazos, Pleasanton, CA 94566

Signature: [Signature] Date: 5/29/98

Marc Jensen of Los Gatos, California, a citizen of U.S.A.. Post office address: P.O. Box 2126, Los Gatos, CA 95031

Signature: [Signature] Date: 5/29/98